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Summary 
Apolipoprotein E (ApoE) plays an important role in the regulation of lipid 
metabolism in the hepatic and central nervous system (CNS). HuApoE4 
carriers have been associated with higher peripheral cholesterol level and 
increased risk for atherosclerosis. Surprisingly, my data showed that huApoE4 
has little impact on brain cholesterol metabolism. HuApoE4 isoform is also 
known to accelerate memory decline in ageing and certain neurological 
diseases but the molecular mechanism remains elusive.  
 
Transgenic mouse models bearing phenotypic resemblance to human diseases 
are commonly used to study and dissect molecular relevant pathways. My data 
showed that an established mouse model for the human Niemann-Pick type C 
(NPC) disease exhibits varying ApoE present in its CNS. Extensive 
neurodegeneration and abnormal metabolic profiles in the CNS have been 
reported. My results showed that the PI3K/AKT signalling pathway was 
disrupted in the CNS of NPC mouse model. The PI3K/AKT pathway plays a 
key role in multiple cellular processes such as glucose metabolism and GSK3β 
activity. 
 
Genetic modified huApoE3/E4 mouse models were used to study the effects 
of huApoE genetic polymorphism. These animals exhibited distinct glucose 
metabolic profiles and changes in the PI3K/AKT signalling pathway. Similar 
observations were made in the peripheral and CNS. These findings uncovered 
potential molecular pathways associated with glucose dysfunction. I have also 
noticed that most of these molecular changes were evident in older mice. 
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These strongly suggest that ageing plays an important role together with the 
huApoE. Collectively, my data suggests a novel role for huApoE in regulating 
brain insulin signalling.  
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1 Introduction 
1.1 Apolipoprotein E (ApoE) 
1.1.1 Characteristics of Apolipoprotein E 
Human ApoE is located on chromosome 19 encoding a 35 kDa 
glycoprotein(Rall, Weisgraber et al. 1982) that exists in 3 isoforms, E2, E3 
and E4 (Mahley 1988; Zannis, Kardassis et al. 1993). Although sequence 
analysis has shown that ApoE4 is the ancestral state in humans (Hanlon and 
Rubinsztein 1995), ApoE3 had increased in frequency through evolution as 
the most common isoform. This is followed by ApoE4 and ApoE2. They 
differ with a single amino acid at position 112 and 158 (Zannis, Breslow et al. 
1982). These crucial amino acid changes alter the charge and stability of ApoE, 
contributing to its distinctive physiological functions (Table 1). 
 
Table 1 Different ApoE isoforms and its allelic frequency in the 
population (Hauser, Narayanaswami et al. 2011).  
ApoE3 is the most common allele among the population. ApoE2 and ApoE4 
differ from ApoE3 by one amino acid at either 112 or 158 position. 
Isoform amino acid 
differences 
Allelic Frequency 
  E2 E3 E4 
ApoE2 Cys 112 Cys 158 E2 1-2% ~15% 1-2% 
ApoE3 Cys 112 Arg 158 E3   ~55% ~25% 
ApoE4 Arg 112 Arg 158 E4     1-2% 
 
ApoE belongs to a group of lipid carrier molecules that is vital in the 
cholesterol homeostasis of the body, both the peripheral and the central 
nervous system (CNS) (Brown and Goldstein 1986). It is one of the key 
constituent of lipoproteins that regulates the metabolism of lipids in the body 
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through ApoE receptors and related proteins. ApoE is widely expressed in 
various tissues with the highest expression in liver and brain.  Emerging 
studies have suggested that its functions may extend beyond lipid metabolism 
to include maintenance of normal brain function and possible involvement in 
neurological diseases (Mahley and Rall 2000; Mahley, Weisgraber et al. 2009). 
Structural variations in ApoE isoforms might affect its preferential binding to 
lipoprotein receptors in the peripheral and CNS which in turn could potentially 
remodel the lipid metabolism and/or neuronal signalling respectively.  
 
1.1.2 Functions of Apolipoprotein E 
1.1.2.1 Peripheral system 
Cholesterol is an essential component of cell structure and source of steroid 
hormones in the cell. The hydrophobic nature of cholesterol presents an 
obstacle to its distribution in the body. Henceforth robust and balance 
mechanisms are in place to maintain the homeostasis of cholesterol in the 
body. Lipid carriers such as apolipoproteins are deployed to package 
cholesterol into lipoproteins in order to be transported around the body. 
 
Cholesterol is delivered to the peripheral tissues from the liver in the form of 
low-density lipoproteins (LDLs) and very low-density lipoproteins (VLDLs). 
The cell cholesterol requirements are met through in situ synthesis and 
absorption of VLDLs and LDLs. Excess cholesterol are subsequently excreted 
from the peripheral tissue in the form of high-density lipoproteins (HDLs) into 
the circulatory system and back to the liver. At the liver, the cholesterol are 
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released from the bile into the intestinal tract to be excreted as faeces or 
reabsorbed. This is known as the reverse cholesterol transport (RCT). 
 
There are six major classes of apolipoproteins and our focus falls on ApoE. 
ApoE is an integral component of chylomicrons, VLDLs and HDLs in the 
peripheral system (Table 2). It operates as part of an anchoring mechanism 
that aids in the transport of triglyceride (TG), phospholipid (PL), cholesteryl 
esters (CE) and cholesterol into cells by mediating the binding and 
internalization of these lipoprotein particles. ApoE has a strong affinity and is 
the main ligand for members of the low density lipoprotein receptor (LDLR) 
family found on liver and other tissues. This super family includes the LDLR, 
LDLR related protein 1 (LRP1), VLDL receptor and ApoE receptor 2 
(apoER2). Interaction of ApoE with LDLR mediates the removal of ApoE-
containing lipoproteins and modulates the homeostasis of lipids in the 
peripheral system. 
 
Table 2 Plasma lipoproteins containing ApoE (Smith, Pownall et al. 1978).  
ApoE is present in three out of the four classes of lipoproteins in the peripheral 
system. 
Properties Chylomicrons VLDL LDL HDL 
Major 
apolipoproteins 
ApoA-I ApoB ApoB ApoA-I 
ApoB ApoC-I   ApoA-II 
ApoC ApoC-II     
  ApoC-III     
  ApoE     
Minor 
apolipoproteins 
ApoA-II ApoA-I ApoC ApoC-I 
ApoE ApoA-II   ApoC-II 
  ApoD   ApoC-III 
      ApoD 
      ApoE 
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ApoE polymorphism has an influence in the plasma cholesterol level 
(Boerwinkle, Visvikis et al. 1987). Clinical studies have shown that ApoE4 is 
associated with higher plasma total cholesterol and LDL, followed by ApoE3 
and ApoE2 (Ehnholm, Lukka et al. 1986; Eichner, Dunn et al. 2002). This is 
largely attributed with ApoE4 preferential binding to VLDL and ApoE3 to 
HDL (Nguyen, Dhanasekaran et al. 2010). Nonetheless, these observations 
may be challenged by individual’s dietary fat intake and other lifestyle 
behaviours (Petot, Traore et al. 2003). 
 
The importance of ApoE in lipid metabolism is asserted with the extensive 
accumulation of lipoproteins in the circulatory system of ApoE-null mouse 
(Plump, Smith et al. 1992). In addition, a Western high fat diet further elevates 
plasma cholesterol and aggravates atherosclerotic lesions (Zhang, Reddick et 
al. 1992). On the other hand, overexpression of ApoE in transgenic mouse 
drastically reduces plasma cholesterol and TG level, consequently eliminating 
diet-induced hypercholesterolemia (Shimano, Yamada et al. 1992). 
 
1.1.2.2 Central nervous system (CNS) 
The human brain contains up to 25% of cholesterol that is essential for myelin 
production, function and integrity. It is vital to maintain the cholesterol 
homeostasis in the CNS (Dietschy and Turley 2004; Saher, Brugger et al. 
2005). The CNS cholesterol is independently regulated from the peripheral 
system. It is believed to be mainly synthesized by glial cells for the neurons 
(Quan, Xie et al. 2003). The process to synthesize cholesterol is energy 
intensive and thus it is more efficient for the astrocytes to carry out this role 
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(Brecht, Harris et al. 2004; Xu, Bernardo et al. 2006). Cholesterol dysfunction 
in the CNS has been associated with ageing and the development of certain 
neurodegenerative diseases such as AD, Parkinson disease (PD) and NPC 
(Simons and Ehehalt 2002; Karten, Hayashi et al. 2005). 
 
The blood brain barrier (BBB) restricts the exchange of lipoproteins and ApoE 
between the central nervous and peripheral systems.  
Henceforth, the lipid composition and regulation in both systems function 
independently. In the CNS, lipoproteins are primary synthesized by glial cells 
(Roheim, Carey et al. 1979; Pitas, Boyles et al. 1987) and ApoE may play a 
pivotal role in the transportation of these packages (Boyles, Zoellner et al. 
1989; Goodrum 1991). An early study had shown that injury to the brain 
resulted in increased ApoE protein in the brain (Poirier, Hess et al. 1991). It 
was proposed that ApoE-containing lipoproteins were taken up by ApoE 
receptor-rich neurons for repair (Ignatius, Gebicke-Harter et al. 1986; Boyles, 
Zoellner et al. 1989). 
 
HuApoE isoforms have been associated with risks to neurological diseases 
(Corder, Saunders et al. 1993; Saunders, Strittmatter et al. 1993; Roses 1996; 
Ashford 2004, Raber, 2004 #296). Other than huApoE isoforms, differential 
expression level of huApoE proteins in the CNS is also linked to neurological 
symptoms such as NPC and AD (Ramaswamy, Xu et al. 2005; Riddell, Zhou 
et al. 2008; Sullivan, Han et al. 2011). More recently, there have been two 
reports suggesting that brain huApoE regulates the clearance of Aβ which is a 
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common hallmark for some neurological diseases, such as Alzheimer’s disease 
(Kim, Jiang et al. 2011; Bien-Ly, Gillespie et al. 2012).  
 
1.2 Glucose metabolism in the CNS 
Glucose is the most common source of energy for the body and it is important 
to maintain its regulation. In the peripheral system, an overdose of blood 
glucose may lead to diabetes mellitus while low blood glucose can result in 
hypoglycaemia (Weyer, Bogardus et al. 1999; Schwartz and Porte 2005). 
Abundant amount of blood glucose will lead to increase metabolism in the 
pancreatic β cells. This leads to an elevation of insulin and kicks off a series of 
insulin signalling linked pathways.  
 
1.2.1 Glucose hypometabolism in diabetic and Alzheimer’s disease 
patients 
Type 2 diabetic mellitus (T2DM) patients typically suffer from glucose 
dysfunction due to impairments in the insulin signalling pathway (Niswender, 
Morrison et al. 2003; Plum, Belgardt et al. 2006). The human brain consumes 
up to 30% of the total body glucose, thus glucose regulation plays an 
important role in the CNS. Any disruption to glucose regulation may affect the 
health of the CNS. It is widely recognized that hypometabolism occurs in 
certain regions of the brain for AD patients and also elderly population 
(Mosconi, Sorbi et al. 2004; Samuraki, Matsunari et al. 2012). It is still unclear 
if hypometabolism is associated to neurodegeneration in the CNS. (Jack, 
Knopman et al. 2010).  
 
8 | P a g e  
 
Emerging studies in human and animal populations support the notion that 
lower brain glucose metabolism may be indicative of cognitive declination 
later in life (Reiman, Caselli et al. 1996; Drzezga, Riemenschneider et al. 2005; 
Reiman, Chen et al. 2005; Caselli, Dueck et al. 2009; Kalpouzos, Chetelat et al. 
2009). It is also noteworthy that most of these studies have associated ApoE4 
as a major genetic risk factor for AD with glucose dysfunction in the CNS. 
 
Epidemiological studies have shown that T2DM is a risk factor for memory 
and learning impairment diseases such as AD (Gispen and Biessels 2000; 
Kopf and Frolich 2009; Sims-Robinson, Kim et al. 2010). In line with these, a 
recent clinical publication cited significantly decrease in the activity of PI3K-
AKT signalling pathway in T2DM and AD patients. This may potentially lead 
to activation of glycogen synthase kinase-3β (GSK3β), the major tau kinase 
(Liu, Liu et al. 2011). 
 
It is also largely believed that glucose transporters 1, 3 and 4 (GluT1, GluT3 
and GluT4) which are found in the CNS may be reduced or desensitized to the 
effects of insulin. This subsequently leads to lower brain glucose metabolic 
rate (Hooijmans, Graven et al. 2007). In light of several other evidences 
(Schubert, Gautam et al. 2004; Watson and Craft 2004; Cole and Frautschy 
2007), the insulin signalling pathway is likely to be defective in neurological 
diseases.  
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1.2.2 Role of insulin in the central nervous system 
Insulin is a hormone that is responsible for the regulation of the blood glucose 
level in the body. It consists of 51 amino acids and is produced by the β-cells 
in the islets of Langerhans of the pancreas. It was believed that pancreas was 
the sole source of insulin for the body and it can be transported across the 
blood brain barrier to the brain only via specialized insulin transporters (Banks 
2004). Recently, more reports seem to favour the idea that the brain itself is 
also capable of synthesizing insulin and this is associated with the survival of 
brain cells (Devaskar, Giddings et al. 1994; Steen, Terry et al. 2005). Brain 
insulin is responsible for the regulation of food intake and body weight 
(Schwartz, Baskin et al. 1999). It has also  has been shown to regulate neural 
development and possibly cognition related functions (Zhao, Chen et al. 1999; 
Zhao and Alkon 2001; Gerozissis 2008). 
 
Insulin receptor (IR) belongs to the receptor tyrosine kinase (RTK) family and 
consists of two (α- and β-) subunits. The alpha subunit of 135 kDa forms the 
extracellular ligand binding protein, while the beta subunit of 95 kDa contains 
the kinase catalytic domain (Taylor, Cama et al. 1992; De Meyts and 
Whittaker 2002). These subunits form a tetrameric structure held together by 
disulphide bonds and span across cell plasma membrane (Olefsky 1990).  
When insulin binds and activates the alpha subunit, it triggers a rapid 
autophosphorylation of IR. This is followed by a cascade of phosphorylation 
events that leads to different biological functions.  
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Insulin receptor is widely expressed in the brain with higher concentration in 
the olfactory bulb, cerebral cortex, hypothalamus and hippocampus. The 
expression of IR appears to be developmentally regulated, with higher 
expression in the early stage and declines with age. It is also noteworthy that 
IR is highly expressed in neurons relative to the glial cells (Havrankova, Roth 
et al. 1978; van Houten, Posner et al. 1979; Werther, Hogg et al. 1987). In the 
CNS, both the peripheral and brain IR can be found in the glial and neuronal 
cells respectively (Adamo, Lowe et al. 1989). Brain IR has a lower molecular 
weight as to peripheral IR due to alternate splicing that results in the deletion 
of its exon 11, otherwise they are largely similar (Heidenreich, Zahniser et al. 
1983; Wozniak, Rydzewski et al. 1993) 
 
Since the discovery of IR in the brain by use of ligand autoradiography 30 
years ago (Havrankova, Roth et al. 1978), researchers have attempted to 
understand the intracellular molecular mechanisms and proteins involved in 
insulin signalling. Valuable information gathered on these pathways served as 
a database for pharmaceutical companies to identify potential therapeutic 
targets.  
 
1.2.3 PI3K/AKT signalling pathway in the central nervous system 
Upon activation of IR, the tyrosine residues within the β-subunit are 
phosphorylated and target insulin receptor substrates (IRS) (White 1997). 
Generally, the two main pathways that are activated by insulin receptor 
include the PI3K-protein kinase B (AKT) and the Ras/mitogen-activated 
protein kinase (MAPK) pathways. Our research focus will remain with PI3K-
11 | P a g e  
 
AKT and it will be further elaborated. Unlike most receptor tyrosine kinases, 
IRS serves as accessory platform for src homology 2 (SH2-) domain 
containing molecules, such as phosphatidylinositol 3-kinases (PI3K) (White 
2002). This cascade of events plays in important part in the insulin signalling 
pathway. Defective IRS has been observed in skeletal muscle of obese and 
type 2 diabetes patients (Danielsson, Ost et al. 2005).  
 
With the recruitment of PI3K, it produces phosphatidylinositol (3, 4, 5)-
trisphosphate (PIP3) from phosphatidylinositol (4, 5)-bisphosphate (PIP2). 
Dysregulation of IRS and PI3K have been observed in the brain samples of 
post mortem AD patients (Moloney, Griffin et al. 2008). This further 
strengthens the link between neurological disease and insulin/IR activation. 
Subsequently, PI3K kicks off another round of events that involves the 
serine/threonine phosphorylation of pleckstrin homology (PH-) domain 
containing proteins which include  3-phosphoinositide dependent protein 
kinase-1 (PDK1), AKT and protein kinase C (PKC) (Alessi and Downes 1998). 
Phosphorylated AKT (p-AKT) has been actively linked to several glucose 
associated functions.  
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Figure 1 Schematic diagram of insulin driven AKT activation 
Insulin binds to extracellular alpha subunit of insulin receptor and triggers 
autophosphorylation the tyrosine residues within the β-subunit of insulin 
receptor. This leads to the activation of IRS. Following the recruitment of 
PI3K, these proteins facilitate the production of PIP3 from PIP2. This protein 
structure then engage PDK1 leading to the activation of AKT. 
 
p-AKT targets GSK3 (Glycogen synthase kinase 3) (Cross, Alessi et al. 1995) 
and AS160 (Kane, Sano et al. 2002) which are involved in glycogen synthesis 
and translocation of glucose transporter to the plasma membrane respectively 
(Sano, Kane et al. 2003). GSK3 activity is inhibited when it is phosphorylated 
at Ser21 and Ser9 of GSK3α and GSK3β respectively. GSK3 activity is also 
associated with the phosphorylation of glycogen synthase (GS) and glycogen 
synthesis activity (Brady, Bourbonais et al. 1998). Phosphorylated AKT has 
also been shown to mediate glucose synthesis through the inhibition of FoxO1 
(Forkhead box O1) (Brunet, Bonni et al. 1999; Kops, de Ruiter et al. 1999). 
Majority of these information are collected from the peripheral system, it is 
presumed that the insulin signalling pathway in the CNS functions in a similar 
manner. Insulin activation triggers several events and proteins, however only a 
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segment has been briefly elaborated. Insulin signalling dysfunction may be the 
result of disruption at any one or more points in the pathway. 
 
1.2.4 Insulin affects cognitive performance 
The association between diabetes and cognitive impairment in human has been 
well documented (Perlmuter, Hakami et al. 1984; Yoshitake, Kiyohara et al. 
1995; Curb, Rodriguez et al. 1999; Gispen and Biessels 2000; Bruce, Casey et 
al. 2003; Munshi, Grande et al. 2006). These data include epidemiological 
studies highlighting hyperinsulinemia as a risk factor for dementia (Ott, Stolk 
et al. 1999; Biessels, Staekenborg et al. 2006). Clinical investigation showed 
improvement in cognitive impaired patients that underwent with insulin 
therapy but these positive effects diminished with prolong usage. However, 
this study is sufficient to demonstrate that the insulin signalling pathway is 
involved in memory and learning (Kern, Peters et al. 2001; Van den Berghe, 
Schoonheydt et al. 2005; Reger, Watson et al. 2008). Interestingly, elderly 
patients with higher insulin levels have higher risk to develop cognitive 
impairment later in life (Stolk, Breteler et al. 1997; Stolk, Pols et al. 1997). 
Significantly lower CSF (Cerebrospinal fluid) insulin levels were measured in 
AD patients in contrast to healthy patients (Craft, Peskind et al. 1998). 
Reduced mRNA and protein levels of insulin have also been reported in 
patients suffering from neurodegenerative disorders such as AD (Steen, Terry 
et al. 2005; Zhao, De Felice et al. 2008). These observational reports suggest 
links between insulin level and cognitive performance, however the molecular 
details of this relationship remains elusive. 
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Several in-vitro studies have been conducted to support earlier clinical 
observations. The addition of insulin protects hippocampal neurons against Aβ 
induced cytoxicity (Takadera, Sakura et al. 1993; Rensink, Otte-Holler et al. 
2004; De Felice, Vieira et al. 2009). Insulin has also been shown to compete 
with Aβ for insulin receptors in neuronal cells. This process results in a 
decrease in the IR/PI3K/AKT signalling pathway and prevents Aβ from 
damaging the neurons (Xie, Helmerhorst et al. 2002; De Felice, Vieira et al. 
2009). Parallel to clinical injection of insulin to the CNS, insulin was able to 
promote dendritic spine formation in primary culture studies . This is possibly 
via the insulin-induced AKT signalling pathway (Lee, Huang et al. 2011). The 
molecular mechanism underlying these observations are not clearly 
understood but it is likely to involve the PI3K/AKT signalling pathway. In 
summary, the balance of insulin plays an important role in cognitive 
performance, particularly in elderly. Other parameters such as the regulation 
and metabolism of glucose in the CNS may contribute to these insulin-
associated effects.  
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1.3 Apolipoprotein E and neurological diseases 
1.3.1 Alzheimer’s disease 
Alzheimer’s disease is a widespread neurodegenerative illness and also the 
leading cause of dementia. Currently AD affects approximately 40% of the 
population over 80 years of age and the loss of memory can be very costly to 
the psychological and economic health of the society. This is especially 
prevalent in developed countries with higher life expectancy. The estimated 
health cost of AD in US is set to exceed 100 billion dollars (Ernst and Hay 
1994) and this is a growing problem in the fast-aging society of Singapore.  
 
The most prominent symptom of AD is declination of recent memory. As the 
disease develops, other cognitive abilities such as language, movement and 
sightedness begin to deteriorate. The disease eventually results in global 
cognitive decline. The classical hallmarks of AD include extracellular amyloid 
plaques consisting of amyloid beta aggregates and intracellular neurofibrillary 
tangles of hyperphosphorylated tau protein (Morris 1997). Clinical diagnosis 
of AD is still in its infancy and there is a lack of established and non-invasive 
approaches to accurately determine the severity or progression of the illness. 
Existing cognitive performance tests are only able to determine the severity of 
the cognitive impairment. To date, confirmed AD patients can only be 
identified through post-mortem brain pathology. 
 
In addition to plaques and tangles, correlation studies have identified ApoE as 
a major risk factor and the most important genetic factor to AD (Corder, 
Saunders et al. 1993; Saunders, Strittmatter et al. 1993; Roses 1996; Ashford 
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2004, Raber, 2004 #296). These associations are supported by population 
studies manifesting severe cognitive declination with the presence of ApoE4 
allele (Jonker, Schmand et al. 1998). However, there is still much discrepancy 
on the potential risks that ApoE4 carriers are exposed to. They include earlier 
onset of AD (Blacker, Haines et al. 1997; Meyer, Tschanz et al. 1998; van der 
Vlies, Koedam et al. 2009), higher rate of developing AD (Kivipelto, Helkala 
et al. 2001; Whitmer, Sidney et al. 2005) and/or accelerated rate of 
progression of AD (Saunders, Strittmatter et al. 1993).  
 
Other than polymorphic differences in ApoE, it is widely agreed that the 
expression level of ApoE may be associated to AD. Earlier evidences indicate 
that huApoE4 protein is less stable as compared to huApoE3 protein (Huang, 
Liu et al. 2001). This instability contributes to lower huApoE4 protein in the 
body due to degradation. This is supported with observations in patients (Eto, 
Watanabe et al. 1986; Gregg, Zech et al. 1986) and animal models (Riddell, 
Zhou et al. 2008).  
 
Interestingly, conflicting clinical data of ApoE level in the CNS have been 
published. No distinct ApoE level change has been observed in patients’ CNS 
(Lehtimaki, Pirttila et al. 1995; Landen, Hesse et al. 1996; Lefranc, Vermersch 
et al. 1996; Pirttila, Soininen et al. 1996; Lindh, Blomberg et al. 1997). 
Significantly lower (Bertrand, Poirier et al. 1995; Beffert, Cohn et al. 1999) 
and higher levels (Harr, Uint et al. 1996; Lambert, Perez-Tur et al. 1997; 
Lindh, Blomberg et al. 1997; Fukumoto, Ingelsson et al. 2003; Bray, Jehu et al. 
2004; Sihlbom, Davidsson et al. 2008) of ApoE were also observed in the 
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CNS of ApoE4 carriers. The varying ApoE level in these clinical samples may 
be due to different sample preparation methods or the specific regions that 
were studied. 
 
In spite of all these, ApoE4 allele is not sufficient for the development of AD 
but more of a supportive role in the disease progression. A multitude of factors 
contributes to AD, they include gender, age, amyloid beta and other related 
diseases such as atherosclerosis and type 2 diabetes. Since the genetic impact 
of ApoE4 is not the principle and sole factor, it is not practical as a form of 
diagnosis for AD. In summary, ApoE is classified as a risk factor for AD but 
the molecular events that precede dementia remain elusive.  
 
1.3.2 Niemann-Pick type C (NPC) disease 
NPC is an inherited autosomal recessive disorder caused by a failure in 
cholesterol trafficking due to a mutation in NPC1 (95% of cases) or NPC2 
protein. NPC1 is a large transmembrane protein of 1278 amino acids. It is 
localized to the late endosomal membrane and has been associated with 
cholesterol trafficking (Higgins, Davies et al. 1999; Wiegand, Chang et al. 
2003). NPC patients exhibit accumulation of unesterified cholesterol and other 
lipids in the peripheral tissues, particularly in the liver and spleen (Beltroy, 
Richardson et al. 2005). The lipid accumulation results in neonatal jaundice 
and liver enlargement which can lead to acute liver failure.  
 
NPC1 deficiency in patients have little effect on the plasma cholesterol 
whereby only an increase in the plasma triglyceride was recorded (Shamburek, 
18 | P a g e  
 
Pentchev et al. 1997; Garver, Jelinek et al. 2009). Oddly, the CNS is uniquely 
spared from similar lipid accumulation and a significant reduction in the 
cholesterol is observed (Vanier 1999). As the disease progresses, patients 
further develop extensive neurodegeneration of the cerebellum, especially in 
the thalamus and the purkinje cell layer (Vanier and Millat 2003). Since no 
effective treatment is available for NPC patients, death typically occurs in 
their teenage years. It is interesting to note that both AD and NPC bear strong 
pathological resemblances such as neurofibrillary tangles, tau pathology and 
increased Aβ generation. (Nixon 2004).  
 
It has been reported that NPC patients with an ApoE4 allele suffer from an 
accelerated form of NPC symptoms (Saito, Suzuki et al. 2002). Notable 
increase in the expression of ApoE was also observed in the CNS of NPC 
transgenic mice (Burns, Gaynor et al. 2003; Li, Repa et al. 2005). These data 
suggest that ApoE may have a role in dysregulation of cholesterol and 
indirectly associated with the progression of neurodegeneration in NPC 
patients.  
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2 Materials and methods 
2.1 Animal models 
Experimental protocols involving the maintenance and euthanasia of 
laboratory mice were in accordance with guidelines approved by the 
Institutional Animal Care and Use Committees (IACUC) at the National 
University of Singapore.  
 
Mice used in the NPC study were homozygous mutant BALB/cNctr-
Npc1m1N/J (NPCNIH) mice (Loftus et al. 1997) from Jackson Immuno-
Research (West Grove, PA, USA) and their wildtype littermates as controls. 
Homozygous NPC mice developed neurological abnormalities at 6–7 weeks of 
age and died within 10–12 weeks of age. Both homozygous NPCNIH and 
control mice were euthanized. Brains were harvested at week 5 and 9, 
corresponding to before and after the onset of neuropathology.  
 
Mice used in the ApoE study were homozygous mutant B6.129P2-Apoetm3 
(APOE*3) Mae N8 mice and B6.129P2-Apoetm3 (APOE*4)Mae N8 mice 
with defined C57BL6/J background (Knouff C et al. 1999) from Taconic 
Farms, Inc (Germantown, NY, USA). Homozygous ApoE mice developed 
abnormal serum lipid profiles under high fat diet according to the huApoE 
isoform which is expressed in the animal. The animals were raised up to 72 
weeks. Both mouse models were euthanized with accordance to IACUC 
guidelines. They were harvested at 12th, 32nd and 72nd week to study the 
effects of huApoE genotype with relevance to ageing.  n = 5 were used from 
each time point in each animal group for all analysis, where possible. 
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Animals were fasted for about 4 hours or more prior to harvest. About 0.7 mL 
of mouse anesthesia from Animal House Unit (AHU) was used via 
intraperitoneal injection. Cardiac puncture were performed with 22G needle 
and the blood were dispensed into EDTA tubes. The blood tubes were 
centrifuged at 1,000 x g for 10 minutes. The plasma were collected and stored 
at -80̊C. The liver, left and right brains were harvested and flushed with sterile 
PBS. They were subsequently stored under -80̊C separately. 
 
2.2 Preparation of brain homogenates 
The whole left hemisphere of the mouse brain was snapped frozen in liquid 
nitrogen. The wet weight of the tissues (in mg) was measured and 1X cell lysis 
buffer (Cell Signalling Technology, Danvers, USA) with Roche protease and 
phosphatase inhibitor cocktail tablets (Roche Molecular Biochemicals, 
Indianapolis, IN, USA). The tissue was prepared at 20% (weight: volume) 
ratio. 
 
The mix was then homogenized with a handheld homogenizer with 3 pulses of 
20 seconds each, with 10 seconds interval on ice to minimize heat degradation 
to proteins. These tissue lysates were then placed on ice for 30 minutes before 
centrifuging them at 6,000 x g for 5 minutes at 4̊C. The soluble portions of the 
lysates were harvested while the insoluble portions were stored at -80̊C 
freezer. The soluble lysates were further distributed into aliquots to minimize 
freeze-thaw over the period of usage. 
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2.3 Preparation of liver homogenates 
The whole liver of the mouse was harvested and snapped frozen in liquid 
nitrogen. The wet weight of the tissues (in mg) was measured and 1X cell lysis 
buffer (Cell Signalling Technology, Danvers, USA) with Roche protease and 
phosphatase inhibitor cocktail tablets (Roche Molecular Biochemicals, 
Indianapolis, IN, USA). The tissue was prepared at 20% (weight: volume) 
ratio. 
 
The mix was then homogenized with a handheld homogenizer with 3 pulses of 
20 seconds each, with 10 seconds interval on ice to minimize heat degradation 
to proteins. These tissue lysates were then placed on ice for 30 minutes before 
centrifuging them at 6,000 x g for 5 minutes at 4̊C. The soluble portions of the 
lysates were harvested while the insoluble portions were stored at -80̊C 
freezer. The soluble lysates were further distributed into aliquots to minimize 
freeze-thaw over the period of usage. 
 
2.4 Protein quantification of lysates 
PierceTM MicroBCA Assay kit (Thermofisher Scientific, Waltham, USA) 
was used to quantify the protein concentration of tissue lysates (2 mg lysed in 
100 μl lysis buffer). Lysates from brain and liver tissues were diluted with 
PBS by 50 and 150 folds respectively. 25 μL of diluted samples alongside 
with the BSA standards were pipetted into microplate wells in duplicates. 200 
μL of working reagent was added to each well and incubated for 30 minutes at 
37̊C before measurements were taken at 562 nm on a Tecan microplate reader. 
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Protein concentrations of samples were then calculated based on the standard 
curve constructed from BSA standards. 
2.5 SDS-PAGE and Western blot analysis 
The final tissue lysates were quantitated and adjusted to 30 - 70 μg of proteins 
per lane with PBS. These protein samples were added with 4X loading buffer 
(42 μL) and subjected to heating at 95°C for 5 minutes. These protein samples 
were then loaded onto a 7.5 - 10% Tris-glycine polyacrylamide gel. 5 μL of 
Precision Plus ProteinTM standard (Bio-Rad Laboratories, Hercules, 
California USA) was used as a molecular weight standard and ran alongside 
with samples in individual lanes. 
 
Gel resolution was performed in Mini-PROTEAN Tetra electrophoretic 
system (Bio-Rad Laboratories). The stacking gel was subjected to 60-90 V for 
approximately 30 minutes, after which the resolving gel was subjected to 90-
120 V until the dye front had reached the bottom of the protein gel. 
 
The gel was removed and the proteins were transferred onto a nitrocellulose 
membrane using Mini Trans-Blot cell (Bio-Rad Laboratories, Hercules, 
California USA) either overnight at 20V or at 110V for 60 mins. The transfer 
efficiency was verified with Ponceau S (Sigma-Aldrich, St-Louis, USA) 
staining and rinsed 3 times with PBSt (PBS with 0.1% Tween 20) to wash off 
Ponceau S stains. The blot was blocked with 5% non-fat milk in PBSt for 30 
minutes with gentle agitation and rinsed twice with PBSt, with agitation of 5 
minutes each time. 
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The blot was then incubated with the intended primary antibody overnight, 
with constant gentle agitation. The HRP-conjugated secondary antibody 
(dissolved in 3% non-fat milk in PBSt) was introduced after the blot has been 
rinsed 3 times with PBSt, and left to incubate for 1 hour under gentle agitation. 
The blot was then rinsed with PBSt 3 times and intended bands were 
visualized using chemiluminescence method with either SuperSignal West 
Dura or SuperSignal West Femto (ThermoFisher Scientific, Waltham, USA) 
based on the protein abundance and sensitivity of the substrate. 
 
The blot was stripped with Restore Western Blot stripping buffer 
(ThermoFisher Scientific, Waltham, USA) and blocked with 5% non-fat milk 
in PBSt prior to incubation with anti-actin primary antibody and the respective 
secondary antibody for final visualization, 
 
All blots were developed using Image Station 4000R (Carestream Health Inc, 
New York, USA). 
 
Table 3 Primary antibodies used in immunoblotting analysis.  
Table includes the name of the targetted protein and its size. The animal 
source, name of the commercial company, catalog number and the dilution 
factor used are also provided. 
Protein target Size Ab source Ab coy Ab cat no. Dilution
Actin 42kDa Mouse Monoclonal Sigma A5316 15,000X
Actin 42kDa Rabbit Monoclonal Sigma A2066 2,000X 
AEBP1 103kDa Rabbit Polycolonal Abbiotec 250461 200X 
AKT 60kDa Rabbit Monoclonal Cell Signaling Technology 4691 1000X 
GluT1 45 + 55kDa Rabbit Polycolonal Millipore 07-1401 500X 
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GluT3 46 + 55kDa Rabbit Polycolonal Millipore 1344 1000X 
GluT4 50kDa Mouse Monoclonal Cell Signaling Technology 2213 1000X 
GSK3β 46kDa Rabbit Monoclonal Cell Signaling Technology 9315 1000X 
huApoE 36kDa Mouse Monoclonal Santa Cruz 13521 200X 
IGF-I Receptor 
β 95kDa Rabbit Monoclonal
Cell Signaling 
Technology 3018 1000X 
Insulin 
Receptor β 95kDa Mouse Monoclonal
Cell Signaling 
Technology 3020 1000X 
IRS1 180kDa Rabbit Monoclonal Cell Signaling Technology 3407 1000X 
IRS2 180kDa Rabbit Monoclonal Cell Signaling Technology 3089 1000X 
p-AKT 
(Ser473) 60kDa Rabbit Monoclonal
Cell Signaling 
Technology 4060 1000X 
p-AKT 
(Thr308) 60kDa Rabbit Monoclonal
Cell Signaling 
Technology 2965 1000X 
PDK1 58-68kDa Rabbit Polycolonal
Cell Signaling 
Technology 3062 1000X 
Phospho-GSK-
3β (Ser9) 46 kDa Rabbit Monoclonal
Cell Signaling 
Technology 9323 1000X 
PI3Kp110 110kDa Rabbit Monoclonal Cell Signaling Technology 4249 1000X 
PI3Kp85 85kDa Rabbit Monoclonal Cell Signaling Technology 4257 1000X 
p-IGF1R / p-
IRb 95kDa Rabbit Polycolonal
Cell Signaling 






Technology 3061 1000X 
PTEN 54kDa Mouse Monoclonal Cell Signaling Technology 9556 1000X 
 
Primary antibodies from Sigma-Aldrich (St Louis, MO, USA), Merck-
Millipore (Massachusetts, USA), Abbiotec (San Diego, CA, USA), Santa Cruz 
Biotechnology (Santa Cruz, CA, USA) and Cell Signaling Technology 
(Danvers, USA) were used for the experiments. The respective catalogue 
number and dilution factor for immunoblotting assays are stated above. 
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Secondary antibodies used include: HRP-conjugated goat anti-mouse IgG 
(Millipore, Massachusetts, USA) and HRP-conjugated goat anti-rabbit IgG 
(Millipore, Massachusetts, USA). Secondary antibodies were used at a dilution 
factor of 1: 5, 000 for immunoblotting assays. 
 
Western blots were analyzed using ImageJ which is available under 
http://rsb.info.nih.gov/ij/. The method of analyzing the Western blot images 
using ImageJ was featured under 
http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-
with-image-j/. This was followed by statistical analysis of the results using the 
Student’s t-test. 
 
2.6 Amplex red glucose assay 
The amplex red glucose kit (Life Technologies, Carlsbad, California, USA) 
was used to determine the glucose content in biological samples. Glucose 
standards ranging from 0 to 100 μM were used to establish a standard curve. 
50 μL of amplex red working solution reagent was added to 50 μL of neat 
tissue lysate samples and incubated for 30 minutes at room temperature in the 
dark. The samples were then measured at excitation of 545 nm and emission 
of 590 nm using a Tecan microplate reader, M200 infinite series (Tecan Group, 
Mannedorf, Switzerland). Values from no glucose controls were used to 
correct background fluorescence. Glucose content of samples were then 
determined in accordance to the kit instruction. 
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2.7 Amplex red cholesterol assay 
The amplex red cholesterol assay kit (Life Technologies, Carlsbad, California, 
USA) was used to determine the cholesterol content in biological samples. 
Tissue lysates were diluted 400-folds in the assay buffer prior to analysis. 
Cholesterol standards ranging from 0-8 μg/ml was used to establish a 
cholesterol standard curve. 50 μL of working solution (Amplex Red 
reagent/HRP/cholesterol oxidase/cholesterol esterase) was added to 50 μL of 
samples/standards. The mixture in 96 microplate format was then incubated 
for 30 minutes at 37̊C in the dark. The plate was then read at excitation 
wavelength of 560 nm and emission wavelength of 590 nm using a Tecan 
microplate reader, M200 infinite series (Tecan group, Mannedorf, 
Switzerland).  Cholesterol content of samples was determined in accordance to 
the kit instruction. 
 
2.8 Insulin ELISA 
The rat or mouse insulin ELISA kit (Millipore, Massachusetts, USA) was used 
for quantification of insulin. 10 μL of diluted protein lysates along with 7 
insulin samples were added to prewashed wells containing 10 μL of assay 
buffers. 80 μL of detection antibodies was added and the mix was incubated at 
room temperature for 2 hours under 450 x g. The wells were then washed 
thrice before the addition of 100 μL of substrate. Readings at absorbance of 
370 nm were measured after 15 minutes of incubation and constantly 
measured at 1 minute intervals using a Tecan microplate reader. 100 μL of 
stop solution was then added when one of the absorbance readings hits 1.8. 
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The plate was then read at 450 nm and 590 nm. The insulin content of the 
samples was then determined in accordance to the kit instruction. 
 
2.9 Real-time PCR analysis 
2.9.1 Isolation of total RNA 
RNA extraction for tissues was done using TRIzol® reagent (Life 
Technologies, Carlsbad, California USA). In general, less than 50 mg of brain 
tissue was used which was then homogenized in 500 μL of TRIzol® reagent 
with a handheld homogenizer (ThermoFisher Scientific, Waltham, USA). To 
ensure complete lysis of tissue, the resulting lysate was further homogenized 
by 10 passages through a 22 G needle. These lysates were then processed 
following manufacturer’s instructions provided in the material datasheet up to 
the RNA precipitation stage. 
The precipitated RNA fraction was subjected to an additional clean-up step 
using the RNeasy Mini kit (Qiagen, Hilden, Germany). RNA samples were 
typically eluted twice in 40 μL of RNase free water provided in the kit before 
they were quantified using the Nanodrop™ 2000. The ratio of the absorbance 
at 260 and 280nm (A260/280) is used to assess the purity of nucleic acids. 
Pure RNA A260/280 is ~2. 
 
2.9.2 Reverse transcription of RNA 
RNA samples were reverse transcribed using the Reverse Transcription 
system (Promega, Madison, USA) with oligo dTs. Typically, 1 or 2 μg of 
RNA was processed each time. The RNA was first heated at 70°C for 10 
minutes and placed on ice before mastermix containing reverse transcriptase 
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was added. The resulting mixture was incubated at 42°C for 20 minutes to 
allow for cDNA synthesis. Lastly, the cDNA was heated at 95°C for 5 minutes 
and placed on ice for another 5 minutes to inactivate the reverse transcriptase 
enzyme. 
 
2.9.3 Real-time PCR 
Each real-time PCR reaction was performed using 50 ng of cDNA. Samples 
were ran in duplicates in volumes of 20 μL each. Specific TaqManR probes 
(Life Technologies, Carlsbad, California USA) were used for the detection of 
various gene products. A typical reaction setup consists of the following 
components: 
Component Volume (μL) 
2× TaqMan® Gene Expression Master Mix   10 uL 
20× TaqMan® probe      1 uL 
Nuclease free water      7 μL 
cDNA        50 ng 
Total volume      20 μL 
Reactions were then run in a 96-well format on a StepOnePlus™ Real-time 
PCR system (Life Technologies, Carlsbad, California USA) using the default 
cycling conditions. For each real-time PCR, a minimum of n=3 set of samples 
was used and each sample run in duplicates to ensure accuracy. Statistical 
analysis of the results was done using the Student’s t-test. 
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2.9.4 TaqMan® probes 
The expression level of the following genes was investigated using real-time 
quantitative PCR and TaqMan probe-based chemistry (Life Technologies, 
Carlsbad, California USA).  
a. Human Apolipoprotein E (Hs00171168_m1).  
b. Mouse Actin (Mm00607939_s1) 
These probes span the exon(s) of the targeted genes and the assays were 
performed according to the manufacturer’s instructions. 
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3 Impaired lipid metabolism and insulin signalling in Niemann-Pick type 
C animal model 
3.1 Introduction 
3.1.1 Apolipoproteins and cholesterol linked diseases 
Apolipoproteins are the key constituents of cholesterol-rich lipoproteins, 
hence several studies have been done in this area. Cholesterol dysfunction has 
been associated with cardiovascular diseases, Niemann-Pick type C and 
metabolic syndrome. Clinical studies have shown that NPC patients carrying 
ApoE4 allele has an accelerated accumulation of phosphorylated tau in 
neurons (Saito, Suzuki et al. 2002). In principle, their data suggested a 
genotype- and age-dependent elevation in the expression of ApoE and ApoD 
(Burns, Gaynor et al. 2003; Li, Repa et al. 2005) with NPC. The lab found a 
similar increase in ApoE at 9 week but not 5 week old mice. Furthermore, 
glycosylation modification in ApoE had also been associated to the 
pathological symptoms of these animals (Chua, Lim et al. 2010).  
 
ApoE and ApoD are major lipid carriers in the CNS. Increased expression of 
ApoE (Iwata, Browne et al. 2005; Karten, Hayashi et al. 2005; Singh and 
Thakur 2010) and ApoD (Franz, Reindl et al. 1999) has long been associated 
with brain injury and neuronal repair. It is presumed that the up regulation of 
these apolipoproteins is part of the body’s attempt to repair damaged cells by 
transporting essential cholesterol to the site. However, little data was able to 
verify if these observations were the causes or consequences of 
neurodegeneration. Alternatively, the increment in the expression of ApoE 
may have been triggered to accelerate the removal of excess cholesterol 
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present in the cells. Nevertheless, most literature agreed that ApoE does play a 
significant role in the disease progression NPCNIH mouse. In view of this 
association, several groups went on to explore the effects of apolipoprotein 
profiles in the CNS of NPCNIH mice. 
 
3.1.2 NPC transgenic mouse model 
Transgenic mouse models with vast phenotypic resemblance to human 
diseases are commonly used to study and dissect relevant molecular pathways. 
BALB/cNctr-Npc1m1N/J (NPCNIH) is an established model for the human 
NPC genetic disorder and it has been widely used over the decade. Mice 
homozygous for the recessive NIH allele of the Niemann Pick type C1 gene 
results in premature truncation of the protein.  
 
The average lifespan of NPCNIH mice is about 75 days (Sarna, Larouche et al. 
2003). By 5 week old, they develop ataxia and other neurological symptoms 
similar to those of the human NPC disease. NPCNIH mice suffer from 
hypercholesterolemia and accumulation of cholesterol in most major organs 
with exception to the brain (Xie, Turley et al. 1999; Xie, Burns et al. 2000). At 
7 week old, gradual losses in myelin cholesterol and brain weight are evident, 
thus reflecting extensive brain dystrophy (Vance 2006).  
 
Conventional ApoE transgenic mouse models are usually complete ablation or 
target-replacement of the gene with different human isoform. These animal 
models do carry some similarities such as cholesterol dysfunction and learning 
impairment (Raber, Wong et al. 1998). The difference in the expression level 
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of ApoE in control and NPCNIH mouse models present an excellent platform 
for our group to investigate how ApoE expression may be associated with 
neurodegeneration and/or other symptoms presented in NPC mouse model. 
 
3.1.3 Cholesterol dysfunction may have resulted in neurological problems 
in NPC patients and mouse models 
Observations made in NPCNIH mouse model strongly suggest that cholesterol 
dysfunction is largely responsible for the disease pathological features. Earlier 
studies hypothesize that impairment in the production of lipoproteins might 
have been the culprit to the neurological symptoms in NPC disease. However 
this was proved otherwise as sequestered lipoproteins from NPC1-deficient 
astrocytes and control cells were found to be structurally and functionally 
similar (Karten, Hayashi et al. 2005).  
 
Significant loss of cholesterol in the brains of NPC patients were described 
and well documented (Vanier 1999). Similar loss of cholesterol in NPCNIH 
mouse brains has also been reported (Xie, Burns et al. 2000). Unlike the 
peripheral system, extensive loss of cholesterol was observed in the CNS. It 
was speculated that intracellular cholesterol accumulation existed as reported 
in animal tissues at preclinical stage (Treiber-Held, Distl et al. 2003) and 
tissue culture studies (Henderson, Lin et al. 2000). Neurons in the CNS were 
unable to tolerate the high accumulation of cholesterol and began to die. This 
is followed by extensive demyelination in the brain. This contributed to the 
cholesterol loss, since myelin is the major source of cholesterol in the brain. 
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3.1.4 NPC patients and mouse models develop metabolic symptoms 
Genome-wide association study conducted on a group of european populations 
identified two NPC1 SNP (single nucleotide polymorphism) that were closely 
linked to obesity (Meyre, Delplanque et al. 2009). In another recent finding, 
significantly higher levels of plasma glucose, insulin and cholesterol were 
measured in NPC+/- heterozygous mice in contrast to the control (Jelinek, 
Millward et al. 2011). These data agree with the author’s earlier report that 
NPC+/- mice were more susceptible to weight gain (Jelinek, Heidenreich et al. 
2010). These animals also appeared to exhibit several other metabolic features 
such as impaired fasting glucose, glucose intolerance, hyperinsulinemia, 
hyperleptinemia and dyslipidemia. In summary, these studies strongly suggest 
that NPC1 gene may be involved in the regulation of glucose. 
  
Fatty liver syndrome due to prolonged lipid accumulation in NPCNIH mouse 
has been associated with severe insulin resistance (Marchesini, Brizi et al. 
1999; Michael, Kulkarni et al. 2000; Marchesini, Bugianesi et al. 2003; Vainio, 
Bykov et al. 2005) and may evolve to a systemic insulin resistance. Under 
high lipid environment, it is speculated that the lipid rich plasma membrane 
may be altered thus changing the expression and functionality of insulin 
receptors (Ikonen and Vainio 2005).  
3.1.5 Hypothesis 
Growing interest in the interplay between insulin and cholesterol metabolism 
(Suzuki, Lee et al. 2010) has driven me to investigate the impact of NPC1 
deficiency on the regulation of glucose and insulin in the CNS. The lab’s 
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earlier publication has also shown that muApoE expression varies in this 
mouse model (Chua, Lim et al. 2010).  
 
Current literature do not fully explain how apolipoproteins may impact on 
abnormal cholesterol and/or glucose regulation, henceforth the NPC mouse 
model provides an excellent tool to explore insulin and cholesterol associated 
pathways. I propose that ApoE may affect the regulation of insulin signalling 
cascade in the CNS of NPCNIH mouse. 
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3.2 Results 
3.2.1 Glucose and insulin profiles of NPCNIH mouse brains 
A significantly lower level of insulin (p ≤ 0.05) was detected in NPCNIH 
mouse brain at both 5th and 9th week time points as compared to Balb/c 
wildtype, 20% and 12% loss respectively (Figure 2).  No significant change 
was observed in the glucose level between Balb/c wildtype and NPCNIH mouse 









Figure 2 Insulin level of Balb/c wildtype and NPCNIH mouse brain lysates  
5 and 9 week old Balb/c wildtype (white bar) and NPCNIH (grey bar) mouse
brain lysates were measured using mouse insulin ELISA kit against a set of
standard. Absolute amount of insulin was measured and normalized against
the protein concentration of brain homogenates. Each value represents the
mean ± SD for individual mouse sample (n  3 at each time point for each
mouse line). * p value ≤ 0.05 using Student’s t-test. 







3.2.2 Western blot analysis of PI3K/AKT signalling pathway in NPCNIH 
mouse brains 
As illustrated in figure 4, there is a notable loss in the expression of IRS1 and 
IRS2 proteins in NPCNIH mouse brain lysates as compared to Balb/c wildtype 
at both 5th and 9th week time points. Significantly lower PI3Kp85 was 
observed in 9 weeks old NPCNIH mouse brain lysates. Activated AKT (p-AKT 
Thr 308 and Ser 473) was also lower in the NPCNIH mouse brain lysate as 
compared to wildtype Balb/c at 5th and 9th week time points (Figure 5). There 
was no change in the expression of both phosphorylated and total PDK1 
proteins at either time points (results not shown).  
Figure 3 Amplex red glucose assays of Balb/c wildtype and NPCNIH 
mouse brain lysates 
5 and 9 week old Balb/c wildtype (white bar) and NPCNIH (grey bar) mouse 
brain lysates were measured using Amplex red glucose kit against a set of 
standard Absolute amount of glucose was measured and normalized against 
the protein concentration of brain homogenates. Each value represents the 
mean ± SD for individual mouse brain sample (n  3 at each time point for 
each mouse line).  * p value ≤ 0.05 using Student’s t-test. 
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Figure 4 Brain insulin receptor substrate (IRS) protein expression level in 
Balb/c wildtype and NPCNIH mouse brain lysates 
(A) Western blot analysis of insulin receptor β (IRβ),  insulin receptor 
substrate 1 (IRS1) and insulin receptor substrate 2 (IRS2). β-actin was 
immnunoblotted  to ensure similar gel loading of the starting material in each 
sample. Densitometry analysis of (B) IRS1 and (C) IRS2 in 5 and 9 week old 
Balb/c wildtype (white bar) and NPCNIH (grey bar) mouse brain lysates were 
performed using the NIH ImageJ software. Each value represents the mean for 
individual mouse brain sample (n = 2 at each time point for each mouse line). 
 
 








Figure 5 Protein expression of key targets in PI3K/AKT signalling
pathway of Balb/c wildtype and NPCNIH mouse brain lysates 
(A) Western blot analysis of PI3Kp85, AKT, p-AKT T308 and S473. β-actin
was immnunoblotted  to ensure similar gel loading of the starting material in
each sample. Densitometry analysis of (B) PI3Kp85, (C) p-AKT T308/AKT 
and (D) p-AKT S473/AKT in 5 and 9 week old Balb/c wildtype (white bar) 
and NPCNIH (grey bar) mouse brain lysates were performed using the NIH 
ImageJ software. Each value represents the mean for individual mouse brain
sample (n = 2 at each time point for each mouse line). 
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3.2.3 Aebp1 activity in the CNS of NPCNIH mouse model 
In both 5 and 9 week old mouse brain lysates, significantly lower expression 
of Aebp1 (Figure 6) was noted. Following up on this finding, increasing 










Figure 6 Protein expression of Aebp1 and PTEN in Balb/c wildtype and
NPCNIH mouse brain lysates 
(A) Western blot analysis of AEBP1 and PTEN. β-actin was immnunoblotted
to ensure similar gel loading of the starting material in each sample.
Densitometry analysis of (B) AEBP1 and (C) PTEN in 5 and 9 week old
Balb/c wildtype (white bar) and NPCNIH (grey bar) mouse brain lysates were
performed using the NIH ImageJ software. Each value represents the mean for
individual mouse brain sample (n = 2 at each time point for each mouse line). 
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3.2.4 GSK3β activity in the CNS of NPCNIH mouse model 
With reference to figure 7, the magnitude of phosphorylation in GSK3β was 
severely diminished in the CNS of NPCNIH mice and this was especially 









Figure 7 GSK3β activity in Balb/c wildtype and NPCNIH mouse brain
lysates 
(A) Western blot analysis of GSK3β and p-GSK3β. β-actin was
immnunoblotted  to ensure similar gel loading of the starting material in each
sample. Densitometry analysis of (B) p- GSK3β in 5 and 9 week old Balb/c
wildtype (white bar) and NPCNIH (grey bar) mouse brain lysates were
performed using the NIH ImageJ software. Each value represents the mean for
individual mouse brain sample (n = 2 at each time point for each mouse line). 
43 | P a g e  
3.2.5 Expression of glucose transporters in the CNS of NPCNIH mouse 
model 
GluT1 are ubiquitously expressed in the body while GluT3 are exclusively 
found in the CNS, in particular the neurons. The results showed that neither 








Figure 8 Expression of glucose transporters in Balb/c wildtype and
NPCNIH mouse brain lysates 
 (A) Western blot analysis of GluT1 and GluT4. β-actin was immnunoblotted
to ensure similar gel loading of the starting material in each sample.
Densitometry analysis of (B) GluT1 and (C) GluT4 in 5 and 9 week old Balb/c
wildtype (white bar) and NPCNIH (grey bar) mouse brain lysates were
performed using the NIH ImageJ software. Each value represents the mean for
individual mouse brain sample (n = 2 at each time point for each mouse line). 
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3.3 Discussion 
3.3.1 Cholesterol dysfunction and abnormal insulin profiles in the CNS of 
NPCNIH mouse model  
Extensive neurodegeneration accompanied by reduction in the cholesterol in 
the brain of NPCNIH mice are relatively well established. Other than 
cholesterol, several groups including our lab had also observed elevations in 
the expression of ApoE and ApoD in these transgenic mice. (Burns, Gaynor et 
al. 2003; Karten, Hayashi et al. 2005; Li, Repa et al. 2005; Chua, Lim et al. 
2010).  
 
As opposed to conventional hypothesis, Xie et al suggested that the 
concentration of cholesterol in the brain of NPCNIH transgenic mice was higher 
than the control. However, this was only observed at an early stage of the 
disease. It is only later in the disease, due to high rate of myelin loss, the 
overall loss of cholesterol in the brain of NPCNIH transgenic mice appeared to 
be significantly higher (Xie, Burns et al. 2000). These speculations were later 
confirmed, as neurons isolated from postnatal NPCNIH mice showed large 
quantities of cholesterol accumulated in the vesicles of these neurons (Karten, 
Vance et al. 2002). Parallel to Xie’s concept, our lab supports the hypothesis 
that cholesterol accumulation took place in the CNS as in all other tissues 
however the brain tissues are less tolerant to the high lipid environment. This 
ultimately led to cell deaths in various part of the CNS and loss of myelin-
associated cholesterol.  
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Although the cholesterol link in NPC patients and transgenic mice has been 
thoroughly explored, limited studies were conducted on other metabolic 
indicators such as glucose and insulin. As suggested earlier, lipid environment 
of primary hepatocytes from NPCNIH mice was shown to regulate the 
expression and functionality of insulin receptor. This is possibly via its plasma 
membrane (Vainio, Bykov et al. 2005). Traditionally, glucose and cholesterol 
metabolism have been separately associated with brain related diseases such as 
Alzheimer’s disease. More recently, there is increasing research on possible 
crosstalk between these two pathways and how they might complement each 
other leading to neurodegeneration (Vainio, Bykov et al. 2005; Taghibiglou, 
Bradley et al. 2009; Block, Dorsey et al. 2010; Sima 2010). The lab found 
significantly lower levels of insulin in 5 and 9 week old NPCNIH mice as 
compared to the control and no difference in the glucose level. It is noteworthy 
that insulin and glucose level in the CNS of transgenic NPCNIH mice were not 
investigated in any previous study. Since insulin profiles from both the 
peripheral and the CNS were shown to differ (Gerozissis, Orosco et al. 1993), 
it is likely that insulin found in the CNS is largely produced in situ. 
Unfortunately no one is able to identify the source or the regulatory 
mechanism of insulin in the CNS yet. 
 
Insulin is a prominent player in the regulation of glucose in the body as it 
mediates the influx and fate of glucose in the cells via glucose transporter and 
glycogen synthase respectively. In view of these data, I was also interested to 
determine the brain glucose levels of these animals and how it may be 
associated to the current observations. However, brain glucose levels between 
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NPCNIH and control animals showed little difference at both time points 
(Figure 3).  
 
3.3.2 Age dependent attenuated PI3K/AKT signalling in NPCNIH mouse 
model 
I have also decided to explore the popular hypothesis; cholesterol metabolism 
affects the functionality of insulin receptors on the plasma membrane of 
neurons. The regulation of IR in a lipid rich environment of NPCNIH cultured 
cells has previously been reported. This study was performed in primary 
NPCNIH mouse hepatocytes (Vainio, Bykov et al. 2005). It is postulated that 
increased amount of cholesterol in the plasma membrane of primary NPCNIH 
mouse hepatocytes altered the composition and fluidity of the plasma 
membrane lipids. Subsequently intervention study further supports this idea; 
removal of excess cholesterol to the culture restored the functionality of 
insulin receptors. 
 
Regulating the cholesterol environment affects the membrane fluidity of 
NPCNIH cells. This in turn may have tremendous impact on the activity of 
surface membrane insulin receptors. Lipid rafts are pockets of cholesterol 
structures that exist in the plasma membrane and the function of proteins (in 
this case IR) in them are influenced by changes in the concentration of 
cholesterol and sphingomyelin in the membrane. With increasing membrane 
cholesterol, the rafts tend to enlarge and vice versa (Henderson, Edwardson et 
al. 2004).  
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Cholesterol-induced insulin resistance observations were made later in 2009 
whereby primary cortical cultures from rat were treated with cholesterol and 
this resulted in an attenuated insulin signalling pathway. The author postulated 
that insulin receptors were recruited into the lipid rafts domains in the plasma 
membrane. This movement rendered the IR less responsive to insulin as 
compared to those located in the non-lipid raft regions (Taghibiglou, Bradley 
et al. 2009).  
 
Significant loss of insulin in NPCNIH mouse brains and possibly reduced 
functionality of insulin receptors encouraged me to study the insulin signalling 
pathway. Insulin receptors may activate IRS1 and IRS2 which are responsible 
for other downstream targets related to insulin and glucose metabolism.  My 
findings demonstrated down regulation of subsequent downstream targets in 
the PI3K/AKT signalling pathway. The targets include IRS1, IRS2, PI3Kp85 
and p-AKTs (Figure 4 and 5). These observations suggested an attenuated 
PI3K/AKT signalling pathway. Activated IRS recruits and activates PI3K 
which is capable of converting membrane lipid PIP2 to PIP3. With this 
conversion, several downstream targets including survival-promoting kinases 
such as AKT are activated. Increasing amount of evidence has also associated 
PI3K signalling to neuronal survival, LTP (long-term potentiation), LTD 
(long-term depression), learning and memory. (Zhao, Chen et al. 1999; Kelly 
and Lynch 2000; Yamaguchi, Tamatani et al. 2001; Zhao and Alkon 2001; 
Sanna, Cammalleri et al. 2002; Chiang, Wang et al. 2010).  
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The full activation of AKT requires PDK1 and PI3K with phosphorylation on 
Threonine 308 and Serine 473. Since no change was observed in PDK and p-
PDK1, it is likely that PDK1 has little or no influence in the diminished level 
of activated AKT. The lower phosphorylation of AKT at site Threonine 308 
and Serine 473 is speculated to be associated with PI3K. In summary, the 
activity of PI3K/AKT signalling pathway is significantly reduced in NPCNIH 
mice. This is possibly attributed by the loss of insulin and/or cell surface IRs 
due to the high lipid environment and/or extensive neuronal cell death.  
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3.3.3 The effects of attenuated PI3K/AKT signalling pathway in NPCNIH 
mouse model 
AKT is actively involved in several cellular mechanisms such as glucose 
metabolism, cell proliferation, cell migration, apoptosis and transcription. 
More importantly, phosphorylated AKT also modulates the activities of 
glucose transporters, glycogen synthase and tau phosphorylation through 
GSK3β. 
 
My data showed lower p-GSK3β Ser 9 in NPCNIH (Figure 7) mice which 
coincided with our earlier p-AKT results. The higher GSK3β activity may 
suggest higher phosphorylation of tau and/or lower expression of glycogen 
synthase which modulates glycogen synthesis in NPCNIH mice. One distinct 
common hallmark of NPC in both patients and NPCNIH mice is 
hyperphosphorylated tau (Love, Bridges et al. 1995; Suzuki, Parker et al. 1995; 
Sawamura, Gong et al. 2001; Bu, Li et al. 2002; Distl, Treiber-Held et al. 
2003). It is speculated that this symptom may be due to the increased GSK3β 
activity in NPCNIH mice. On the other hand, it is uncertain if GSK3β is solely 
responsible as several other kinases such as MAP kinase and cdk5 (Cyclin-
dependent kinase 5) were reported to induce hyperphosphorylated tau. Further 
analysis on the tau residues which have been phosphorylated will be necessary 
to identify potential kinases involved. A detail table of tau phosphorylation 
and corresponding kinases is available under 
http://cnr.iop.kcl.ac.uk/hangerlab/tautable.  
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Figure 9 Schematic diagram of how ApoE may modulate GSK3β activity 
in the CNS of NPCNIH mice  
The lipid-rich environment in NPCNIH mice inhibits the activity of insulin, IR 
and/or IRS. This significantly lowered the expression of both IRS and AEBP1. 
Further downstream, the phosphorylation of AKT diminished via two possible 
pathways, PI3K and PTEN. The activity of GSK3β is inhibited when 
phosphorylated. This led to higher GSK3β activity in the CNS of NPCNIH mice.  
 
The only publication that had investigated the PI3K/AKT signalling pathway 
in the CNS of NPCNIH mice was by Bi et al in 2005 (Bi, Liu et al. 2005). 
Surprisingly, most of their data indicated an elevation in AKT activity and 
relevant molecules as opposed to the lab’s findings. They postulated that 
higher AKT activity may lead to neurodegeneration involving TNFα (Tumor 
necrosis factor-alpha) and GSK3β. Distinctions between the results may be 
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due to the different time points and the methodologies samples were obtained. 
Results presented in Bi et al were derived from animal brains varying from 1-4 
weeks while our samples were from 5-9 week old mice. It is arguable that 
subtle age differences have little influence in the observations. On the contrary 
it is noteworthy that most of the transgenic mice pathological features only 
surface from the 5th week. 
 
Phosphorylated AKT is involved in several other physiological functions apart 
from mediating GSK3β. It has been shown to alter GluT trafficking from 
intracellular vesicles to the plasma membrane via AS160. Impaired AS160 
transgenic mice exhibited impaired glucose homeostasis and insulin sensitivity 
(Kane, Sano et al. 2002; Sano, Kane et al. 2003; Ng, Ramm et al. 2008; Chen, 
Wasserman et al. 2010). Similar levels of glucose were detected in the NPCNIH 
and control mice, suggesting that the activity of GluT might not have been 
altered in these transgenic animals. We were unable to determine the bio-
activity of GluT on the plasma membrane however little differences were 
observed in GluT protein level between the CNS of both diseased and 
wildtype mouse models (Figure 8). FoxO1 transcription factor which promotes 
the expression of gluconeogenic enzymes is also regulated by AKT. It is 
negatively regulated by the PI3K/AKT signalling pathway and has been 
shown to be compromised under insulin resistant conditions (Brunet, Bonni et 
al. 1999; Kops, de Ruiter et al. 1999). Together, AKT is largely recognized as 
the key protein actively involved in glucose metabolism through various 
avenues. In spite of these, significant studies are still required to decipher its 
role under a lipid-rich environment.  
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3.3.4 Aebp1 mediated AKT signalling 
Other than the PI3K/AKT signalling pathway, I was also interested in other 
molecules that may be associated to ApoE and contribute to the downstream 
GSK3β activity. Aebp1 is an 82 kDa transcriptional repressor and is 
ubiquitously expressed, with exceptionally high expression in the adipose, 
macrophage, liver, lung, spleen and brain (Ro, Kim et al. 2001). Existing 
literature indicate that it holds key regulatory roles in adipogenesis, obesity 
(Ro, Zhang et al. 2007), energy homeostasis (Zhang, Reidy et al. 2005) and 
more recently atherosclerosis (Bogachev, Majdalawieh et al. 2011). Aebp1 has 
also been associated with cholesterol metabolism and inflammation through 
peroxisome proliferator-activated receptor gamma 1 (PPARγ1) and liver X 
receptor alpha (LXRα). Aebp1 overexpression in macrophages has been 
shown to reduce both PPARγ1 and LXRα (Majdalawieh, Zhang et al. 2006) in 
cholesterol homeostasis (Tontonoz, Nagy et al. 1998; Venkateswaran, Laffitte 
et al. 2000; Chawla, Boisvert et al. 2001). 
 
My findings indicated diminishing expression of Aebp1 and up regulation of 
PTEN (Phosphatase and tensin homolog) (Figure 6) in NPCNIH mice which are 
in line with the initial results from the PI3K/AKT signalling pathway. The 
combination of increased PTEN and reduced PI3K lead to significantly 
lowered AKT activity in NPCNIH mice. These data further strengthen our 
previous result and suggest that PI3K/AKT pathway may not be the sole 
mediator of AKT phosphorylation in NPCNIH mice. 
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The interaction between Aebp1 and PTEN was first established using yeast 
two hybrid (Gorbenko, Kuznetsov et al. 2004), subsequently experiments then 
showed that Aebp1 negatively regulates PTEN (Ro, Zhang et al. 2007). PTEN 
has also been identified as a negative regulator of insulin signalling and 
sensitivity as it down regulates the pro-survival serine/threonine protein kinase 
AKT. Tissue-specific PTEN knockout mice exhibited significant improvement 
in glucose tolerance and insulin sensitivity (Kurlawalla-Martinez, Stiles et al. 
2005). It is possible that PTEN may be associated with the phosphorylation 
level of AKT and GSK3β activity. This assumption was partially proven in 
Ro’s co-immunoprecipitation study whereby Aebp1 knockout mice displayed 
significantly lower p-AKT Thr 308(Ro, Zhang et al. 2007). In spite of these, 
these mice did not develop any symptoms that are associated with a defective 
glucose metabolism similar to our NPCNIH mice. This phenomenon may be 
tissue specific as altered AKT activation was only reported in the white 
adipose tissues but not the skeletal muscles. My data may prove valuable as 
these observations have yet to be reported in the CNS of NPC patients/animals. 
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Figure 10 Schematic diagram proposing possible links across NPC1, 
ApoE and lipid metabolism in the CNS 
In a high lipid environment, the PI3K/AKT signalling pathway was 
significantly reduced and results in elevated GSK3β activity. The expression 
of Aebp1 was also severely diminished as the body attempted to clear the lipid 
by up regulating key cholesterol mediators. Both effects synergistically 
contributed to the elevated activity of GSK3β via the PTEN/AKT signalling 
pathway. 
  




In conclusion, the lab has explored the possible influence of ApoE-driven lipid 
regulation on PI3K/AKT signalling pathway. It is important to recognize that 
ApoE and cholesterol metabolism may carry key contributions to insulin and 
glucose regulation in the CNS. Although insulin signalling and lipid 
dysfunction have often been associated with metabolic diseases, insufficient 
data are available to establish a direct link between these systems. My data 
provided clues and further understanding to how differential apolipoprotein 
expression may have resulted in a lipid-overwhelmed CNS which in turn led 
to an attenuated PI3K/AKT signalling (Figure 10). I have also brought forward 
a possible molecular pathway and role of Aebp1 in the CNS (Figure 10).  
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CHAPTER 4 
HUMAN APOLIPOPROTEIN E 
POLYMORPHISM AFFECTS BRAIN INSULIN 
SIGNALLING IN A MOUSE MODEL 
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4 Human apolipoprotein E polymorphism affects brain insulin signalling 
in a mouse model 
4.1 Introduction 
4.1.1 Human apolipoprotein E isoforms and diseases 
Limited literature is available on human apolipoprotein E (huApoE) function 
in the brain. Although it has been associated with higher risk of 
hypercholesterolemia and dementia with ageing, the underlying mechanism 
remains elusive. As described in the first chapter, there are three major 
huApoE isoforms, E2, E3 and E4 (Mahley 1988. Majority of the population 
are huApoE3 carriers while huApoE4 is a strong genetic risk factor for 
atherosclerosis and AD {Hauser, 2011 #710; Zannis, Kardassis et al. 1993). 
Other than huApoE isoforms, the differential expression level of huApoE 
proteins in the CNS is also linked to neurological symptoms such as NPC and 
AD (Ramaswamy, Xu et al. 2005; Riddell, Zhou et al. 2008; Sullivan, Han et 
al. 2011).  
 
4.1.2 Knowledge from NPC studies 
In the earlier chapter, varying insulin profiles and  mouse apolipoprotein E 
(muApoE) between NPCNIH and wildtype mouse models was reported in our 
lab (Chua, Lim et al. 2010). Based on these observations, I decided to explore 
the activity of PI3K/AKT signalling pathway in NPCNIH mouse model. 
Proteins involved in PI3K/AKT signalling pathway were significantly down 
regulated with age when most of the neurological symptoms surfaced. Based 
on these findings, I speculated possible correlation between cholesterol and 
PI3K/AKT signalling pathway involving ApoE expression.  
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HuApoE3 and E4 mouse models are ideal tools to investigate how ApoE 
isoforms may affect cholesterol metabolism and PI3K/AKT signalling 
pathway. 
 
4.1.3 HuApoE targeted replacement (TR)mouse model 
There are several human ApoE transgenic mice available and they are all 
created on ApoE knock-out background. These animals differ on the promoter 
driving the expression of huApoE. These include the glial fibrillary acidic 
protein (GFAP) promoter which is largely found within glial cells (Sun, Wu et 
al. 1998; Holtzman, Bales et al. 2000); the neuron-specific enolase (NSE) 
promoter which is largely found within neuronal cells (Raber, Wong et al. 
1998; Buttini, Orth et al. 1999) and lastly, the endogenous mouse ApoE 
promoter which expresses the designated huApoE  in the huApoE targeted 
replacement (TR) mouse models (Piedrahita, Zhang et al. 1992; Sullivan, 
Mezdour et al. 1998; Knouff, Hinsdale et al. 1999). 
 
Studies have shown that both GFAP-huApoE and NSE-huApoE transgenic 
mice exhibit varying degrees of cognition defects (Raber, Wong et al. 1998; 
Raber, Wong et al. 2000; Hartman, Wozniak et al. 2001). On top of that, 
difference in gender susceptibility has also been reported (Raber, Wong et al. 
2000; Hartman, Wozniak et al. 2001). These labs postulated that marked 
differences are contributed by the different expression profiles of huApoE due 
to the promoter. Henceforth, the usage of KI animals driven by the native 
mouse ApoE promoter is relevant to this study.  
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This mouse model of choice (B6.129P2-Apoetm3(APOE*3/4)Mae N8) has a defined 
C57BL6/J background and is homozygous for a human ApoE3 or ApoE4 gene 
targeted replacement of the endogenous mouse ApoE. It expresses huApoE 
driven by the muAPoE regulatory sequences. Abnormal serum lipid profiles 
and atherosclerotic symptoms only surfaced under high-fat diet for both 
huApoE TR mouse.  Although the huApoE4 mouse model develops more 
severe atherosclerotic lesions and twice the level of cholesterol than in 
huApoE3 mouse model (Knouff, Hinsdale et al. 1999). 
 
4.1.4 HuApoE expression profiles in ApoE3/4 carriers and B6.129P2-
Apoetm3(APOE*3/4)Mae N8 mouse models 
Current literature suggests that huApoE expression in these knock-in mouse 
models display regional differences although they are both driven by the same 
muApoE promoter. Sullivan and collaborators showed that the distribution of 
plasma lipoproteins and ApoE differed between huApoE3, E4 and wild type 
mice kept on a normal chow diet (Sullivan, Mezdour et al. 1997; Sullivan, 
Mace et al. 2004). On top of that, similar huApoE expression variation was 
observed in clinical brain samples between ApoE3 and ApoE4 allele carriers 
(Sullivan, Mace et al. 2004; Ramaswamy, Xu et al. 2005). 
 
CSF of huApoE4 TR mice has been show to contain fewer ApoE molecules as 
compared to the huApoE3 TR mouse model (Riddell, Zhou et al. 2008). 
Similar observation was observed in individuals with ApoE4 alleles, whereby 
significantly lower ApoE was detected in comparison to those without an 
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ApoE4 allele (Larson, Ordovas et al. 2000; Poirier 2005). Vice versa, we also 
found contradicting reports of higher ApoE in brains and plasma of AD 
patients (Artiga, Bullido et al. 1998). Interestingly, under stress conditions, 
intense expression of ApoE was observed in injured neurons and in response 
to excitotoxic injury (Xu, Bernardo et al. 2006).  
 
These observations are particularly interesting since both huApoE3 and 
huApoE4 are targeted replacement for muApoE. Both animals are expected to 
exhibit comparable level of huApoE but it appears that this is not the case. 
This suggests that the disparity in huApoE protein level may be regulated by 
both the expression and also the stability of the protein.  
 
Higher huApoE4 degradation was observed in human astrocytoma cell lines 
and huApoE4 TR mouse brain as compared to huApoE3. This led the author 
to postulate that huApoE4 has poorer protein stability, thus a higher tendency 
to degrade (Riddell, Zhou et al. 2008). These findings further complicate my 
current study as isoform differences may affect the protein level of huApoE 
present in the CNS of both human and mouse. 
 
4.1.5 Cholesterol profiles in ApoE3/4 carriers and B6.129P2-
Apoetm3(APOE*3/4)Mae N8 mouse models 
As discussed in the introduction, ApoE plays a pivotal role in the 
transportation of cholesterol in both the peripheral and central nervous system. 
These evidence led research groups to look into the cholesterol metabolism of 
huApoE TR mouse model. Marked decrease in the brain cholesterol of 
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huApoE4 TR as compared to WT mouse models (Hamanaka, Katoh-Fukui et 
al. 2000). No significant difference in the serum cholesterol level was 
observed between huApoE3 and E4 TR mouse models under normal diet 
(Mann, Thorngate et al. 2004). 
 
Effective delivery of cholesterol has been observed in huApoE3 as compared 
to huApoE4 in primary astrocytes culture (Gong, Kobayashi et al. 2002). It is 
postulated that less effective transportation of lipids in ApoE4 carriers may 
have an effect on myelin repair in the CNS. This is particularly prominent later 
in life with increased age and myelin deterioration.  
 
4.1.6 Hypercholesterolemia associated glucose and insulin profiles 
Literature studies suggest huApoE isoform and/or expression variations may 
affect cholesterol and insulin profiles. Similarly, glucose hypometabolism 
have been observed in certain brain regions of ApoE4 allele carriers (Lee, Lee 
et al. 2003; Mosconi, Sorbi et al. 2004; Drzezga, Riemenschneider et al. 2005; 
Reiman, Chen et al. 2005; Langbaum, Chen et al. 2010) 
 
Genetically obese (ob/ob) mice and rats under high fat diet induced obesity 
have significantly higher serum cholesterol and lower ApoE mRNA as 
compared to control diet animals. Furthermore, intracerebroventricular 
infusion of ApoE and injection of anti-ApoE to the serum have been shown to 
regulate food intake which in turn contributes to dietary cholesterol in these 
animals (Shen, Tso et al. 2008).  
 
62 | P a g e  
 
Cholesterol has been shown to induce insulin resistance in rat primary cortical 
cultures. Cholesterol treated cells exhibit an attenuated insulin signalling 
pathway. It renders insulin receptors less responsive to insulin (Taghibiglou, 
Bradley et al. 2009). These observations proposed strong links across huApoE 
isoform, cholesterol metabolism and insulin signalling. 
 
4.1.7 Experimental considerations 
The huApoE4 isoform is associated with higher risk of cholesterol dysfunction 
and neurological diseases, especially in older adults. Since ageing is an 
important factor, the animals were studied up to 72 weeks to investigate the 
effect of ageing on top of huApoE isoform differences. Both huApoE3 and 
huApoE4 TR mice were studied across three separate time points to monitor 
the progressive effects of ageing and varying huApoE isoforms. 
 
Gender plays an important role in certain genetic risk disease. It has been 
reported that female gender is at a higher risk for neurological disease 
(Darreh-Shori, Brimijoin et al. 2006). On top of that, female NSE-ApoE4 
mouse model has been shown to be more susceptible to cognitive deficits 
(Raber, Wong et al. 2000). Coincidentally, ApoE isoform and gender have 
been shown to influence glucose regulation in AD patients (Aisen, Berg et al. 
2003). In view of these considerations, only female huApoE TR mice were 
used for this study. 
 
Cholesterol, glucose and insulin assays were conducted on huApoE TR mouse 
brain lysates and plasma to determine potential physiological differences in 
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these animals. Circulating blood is able to transverse the blood brain barrier. It 
is important to include the serum/plasma analysis in this study as it is the sole 
transit between the peripheral and CNS. 
 
4.1.8 Hypothesis 
It is evident that differential ApoE protein level is associated with the CNS 
lipid profile. It is may also be affecting glucose and/or insulin metabolism 
through the PI3K/AKT signalling pathway. Earlier studies on NPC mouse 
models support this notion.  
 
I hypothesized huApoE isoform differences together with ageing may affect 
glucose metabolism in the CNS. There is limited literature associating 
huApoE and glucose metabolism in the CNS. On top of that, I was unable to 
find any publication that has addressed glucose metabolism in huApoE TR 
mouse models over a time course. The academic impact of deciphering this 
molecular mechanism is significant and it may allow us to identify other 
potential risks of huApoE genetic variation.  
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4.2 Results 




No significant change was observed in the cholesterol content of both brain 
and plasma (Figure 11A and 11B) of huApoE3 and huApoE4 TR mice at 12, 
32 and 72 week old mouse brain lysates and plasma. 
  
Figure 11 Total amount of cholesterol in plasma and brain lysates of
huApoE3 and huApoE4 TR mice 
Amplex red cholesterol assays of samples from (A) brain lysates, (B) plasma
across all three time points (12th, 32nd and 72nd week) of female huApoE3
(white bar) and female huApoE4 (grey bar) TR mice. The brain lysates was
normalized to its total protein measured via BCA method. The plasma samples
were normalized to its volume. Each value represents the mean ± SD for
individual mouse brain sample (n = 5 at each time point for each mouse line).
Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p value ≤ 0.001 using
Student’s t-test. 
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Figure 12 Relative quantification of huApoE mRNA in the brain of
huApoE3 and huApoE4 TR mice  
∆∆Ct analysis was performed with Ct values obtained with Taqman hydrolysis
assays and normalized against β- actin for female huApoE3 (white bar) and
female huApoE4 (grey bar) TR mice. Each value represents the mean ± SEM
for individual mouse brain sample (n  3 at each time point for each mouse
line). Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p value ≤ 0.001 using
Student’s t-test. 









No significant change was observed in huApoE mRNA level (Figure 12) 
across 12, 32 and 72 week old female mouse brain lysates. Further protein 
analysis via Western blot indicates that there is little change in the huApoE 
protein expression level of 12 week old female mouse brain lysates. However, 
significantly lower huApoE protein expression in huApoE4 TR mice at 32 
week old (-38%) and 72 week old (-45%) female mouse models (Figure 13). 
Figure 13 Brain huApoE protein expression level in the brain of 
huApoE3 and huApoE4 TR mice 
Western blot analysis of human Apolipoprotein E (huApoE) and β-actin 
was immnunoblotted to ensure similar gel loading of the starting material in 
each sample. Densitometry analysis of huApoE relative to β-actin level in 
the brain lysates of female huApoE3 (white bar) and huApoE4 (grey bar) 
TR mice were performed using the NIH ImageJ software. Each value 
represents the mean ± SEM for individual mouse brain sample (n = 3 at 
each time point for each mouse line). Whereby, * p value ≤ 0.05, ** p value 
≤ 0.01, *** p value ≤ 0.001 using Student’s t-test. 
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4.2.3 Glucose and insulin level in the brain and plasma of female huApoE 








Figure 14 Total glucose and insulin in brain lysates of huApoE3 and
huApoE4 TR mice 
Glucose assays of samples from brain lysates across all three time points (12th,
32nd and 72nd week) of female huApoE3 (white bar) and female huApoE4 (grey
bar) TR mice. Insulin assays of samples from brain lysates across all three time
points (12th, 32nd and 72nd week) of female huApoE3 (solid line) and female
huApoE4 (dotted line) TR mice Glucose and insulin readings were normalized
to its total protein measured via BCA method. Each value represents the mean
± SD for individual mouse brain sample (n = 5 at each time point for each
mouse line). Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p value ≤ 0.001
using Student’s t-test. 








Figure 15 Total glucose and insulin in plasma samples of huApoE3 and
huApoE4 TR mice 
Glucose assays of plasma samples across all three time points (12th, 32nd and
72nd week) of female huApoE3 (white bar) and female huApoE4 (grey bar) TR
mice. Insulin assays of plasma samples across all three time points (12th, 32nd
and 72nd week) of female huApoE3 (solid line) and female huApoE4 (dotted
line) TR mice. Glucose and insulin readings were normalized to the volume.
Each value represents the mean ± SD for individual mouse plasma sample (n  =
5 at each time point for each mouse line). Whereby, * p value ≤ 0.05, ** p
value ≤ 0.01, *** p value ≤ 0.001 using Student’s t-test. 
69 | P a g e  
 
Brain lysates showed significant loss of total glucose across all time points 
(Figure 14). -51%, -27% and -34% losses in huApoE4 as compared to 
huApoE3 TR at 12, 32 and 72 week old mouse brain lysates respectively. 
Significant increase of insulin (+25%) was only found in 72 week old 
huApoE4 TR mouse brain samples while there is no change in 12 and 32 week 
old brain samples (Figure 14). 
 
Plasma samples from both huApoE3 and huApoE4 TR mice exhibit similar 
profiles (Figure 15). This is particularly interesting as the profiles of both 
glucose and insulin in the plasma differ from the profiles in the CNS.  
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4.2.4 PI3K/AKT protein profile in the CNS of huApoE3 and huApoE4 TR 
mice 
No significant change was observed in protein expression of IRS1 in the brain 
lysate of both mouse models across all three time points (Figure 16A and 16B). 
Notable up-regulation of IRS2 was observed in 12 week old huApoE4 TR 
mice (+68%). However, the trend reversed in 72 week old huApoE4 TR mice, 
with significant loss of IRS2 (-46%) in the CNS (Figure 16A and 16C). 
 
IRβ protein expression was relatively consistent between huApoE3 and 
huApoE4 TR mouse models at 12th, 32nd and 72nd week time point (Figure 
17A and 17B). Significantly higher expression of IGF1Rβ (Insulin growth 
factor 1 receptor-beta) was observed in huApoE4 TR mice at 12th (+104%) 
week time point (Figure 17A and 17C). The activities of these proteins were 
quantitated by targeting p-IRβ and p-IGF1Rβ. Notable losses of p-IRβ and p-
IGF1Rβ were observed via Western blot densitometry (Figure 17A and 17C) 
in the last two time points, 32nd (-46%) and 72nd (-53%) weeks. 
 
Other than IRS proteins, PI3K proteins are also involved in the activation of 
AKT. Western blot densitometry showed 54% and 51% loss of PI3K p85 
(Figure 18A and 18C) in huApoE4 (as compared to huApoE3 TR mouse) 32 
and 72 week old female mice respectively. On the hand, I did not observe any 
significant change in the expression of PI3K p110 (Figure 18A and 18B) in 
the brain 
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Figure 19A and 19C showed comparable expression of AKT in both huApoE3 
and huApoE4 TR mice at all three time points. Further analysis was conducted 
on both p-AKT S473 (Figure 19B) and T308 (Figure 19D) to study AKT 
activity in both mouse models. Significant loss of p-AKT S473 was observed 
in 72 week old huApoE4 (-39%) as compared to the huApoE3 TR mice. 
Similarly, significant loss of p-AKT T308 was observed in both 32 (-61%) and 
72 (-49%) week old huApoE4 relative to huApoE3 TR mice. 
 
Figure 20 showed notable loss of GluT4 (-48%) in female huApoE4 as 
compared to huApoE3 TR mice at the 72nd week time point. Comparable 
expression of GluT4 was expressed in earlier time point of 12th and 32nd week 
time points. 
  







Figure 16 Brain insulin receptor substrate (IRS) protein expression level
of huApoE3 & E4 TR mice  
(A) Western blot analysis of insulin receptor substrate 1 (IRS1) and insulin
receptor substrate 2 (IRS2). β-actin was immnunoblotted  to ensure similar gel
loading of the starting material in each sample. Densitometry analysis of (B)
IRS1 and (C) IRS2 in female huApoE3 (white bar) and female huApoE4 (grey
bar) TR mice were performed using the NIH ImageJ software. Each value
represents the mean ± SEM for individual mouse brain sample (n = 3 at each
time point for each mouse line). Whereby, * p value ≤ 0.05, ** p value ≤ 0.01,
*** p value ≤ 0.001 using Student’s t-test. 








Figure 17 Brain insulin receptor (IR) protein expression level of
huApoE3 & E4 TR mice 
(A) Western blot analysis of phosphorylated insulin receptor β (p-IRβ),
phosphorylated insulin growth factor receptor β (p-IGFRβ), insulin receptor
β (IRβ) and insulin growth factor receptor β (IGF1Rβ). β-actin was
immnunoblotted  to ensure similar gel loading of the starting material in each
sample. Densitometry analysis of (B) p-IRβ + p-IGFRβ , (C) IRβ and (D)
IGF1Rβ relative to β-actin level in female huApoE3 (white bar) and female
huApoE4 (grey bar) TR mice were performed using the NIH ImageJ
software. Each value represents the mean ± SEM for individual mouse brain
sample (n = 3 at each time point for each mouse line). Whereby, * p value ≤
0.05, ** p value ≤ 0.01, *** p value ≤ 0.001 using Student’s t-test. 










Figure 18 Brain phosphatidylinositol 3-kinases (PI3K) protein expression
level of huApoE3 & E4 TR mice across 12-72 weeks.  
(A) Western blot analysis of phosphatidylinositol 3-kinases p110 (PI3K p110)
and phosphatidylinositol 3-kinases p85 (PI3K p85). β-actin was
immnunoblotted  to ensure similar gel loading of the starting material in each
sample. Densitometry analysis of (B) PI3K p110, (C) PI3K p85 relative to β-
actin level in female huApoE3 (white bar) and female huApoE4 (grey bar) TR
mice were performed using the NIH ImageJ software. Each value represents
the mean ± SEM for individual mouse brain sample (n = 3 at each time point
for each mouse line). Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p
value ≤ 0.001 using Student’s t-test. 









Figure 19 Brain AKT protein expression level of huApoE3 & E4 TR mice 
(A) Western blot analysis of phosphorylated AKT Serine 473 (p-AKT S473),
phosphorylated AKT Threonine 308 (p-AKT T308) and AKT. β-actin was
immnunoblotted  to ensure similar gel loading of the starting material in each
sample. Densitometry analysis of (B) p-AKT S473, (C) AKT and (D) p-AKT
T308 relative to β-actin level in female huApoE3 (white bar) and female
huApoE4 (grey bar) TR mice were performed using the NIH ImageJ software.
Each value represents the mean ± SEM for individual mouse brain sample (n =
3 at each time point for each mouse line). Whereby, * p value ≤ 0.05, ** p
value ≤ 0.01, *** p value ≤ 0.001 using Student’s t-test. 









Figure 20 Brain glucose transporter 4 protein expression level of huApoE3 
& E4 TR mice  
Western blot analysis of glucose transporter 4 (GluT4). β-actin was 
immnunoblotted  to ensure similar gel loading of the starting material in each 
sample. Densitometry analysis of GluT4 relative to β-actin level in female 
huApoE3 (white bar) and female huApoE4 (grey bar) TR mice were performed 
using the NIH ImageJ software. Each value represents the mean ± SEM for
individual mouse brain sample (n = 3 at each time point for each mouse line). 
Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p value ≤ 0.001 using 
S d ’
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4.3 Discussion 
4.3.1 Cholesterol, glucose and insulin profiles in the CNS of human 
apolipoprotein TR mouse models 
There was no difference in the brain cholesterol level between both huApoE3 
and E4 TR mice (Figure 11A). Earlier studies in NPC mouse model suggest 
that the level of ApoE protein may be associated with the brain cholesterol 
level. HuApoE expression in both mouse models differ significantly (Figure 
12), however it does not seem to have any impact on brain cholesterol level. It 
is possible other than ApoE, other apolipoproteins such as ApoD (Franz, 
Reindl et al. 1999) may be regulating the cholesterol level. It is also 
noteworthy that extensive loss of cholesterol found in NPC mouse model was 
speculated to be the result myelin loss which has not been reported in 
huApoE4 TR mouse model. 
 
I did not find any major difference in the plasma cholesterol of both huApoE3 
and E4 TR mice (Figure 11B). This is in line with current literature as 
abnormal lipid metabolism and atherosclerotic symptoms were only observed 
when these animals underwent high fat diet. 
 
Other than cholesterol metabolism, dysregulated glucose metabolism has also 
been associated with neurological diseases such as AD. Lower brain glucose 
metabolism together with ApoE4 have been associated with cognitive 
declination later in life (Reiman, Caselli et al. 1996; Drzezga, 
Riemenschneider et al. 2005; Reiman, Chen et al. 2005; Caselli, Dueck et al. 
2009; Kalpouzos, Chetelat et al. 2009). PI3K/AKT signalling pathway which 
78 | P a g e  
 
plays an important role in glucose metabolism has been found to be altered 
(previous chapter) in NPC disease mouse model. In addition, insulin profile in 
NPC disease mouse model has also been shown to be affected (Ong, Lim et al. 
2012). Owning to the above evidences, glucose and insulin assays were 
performed on brain samples of both huApoE TR mice. 
 
Lower glucose levels were observed in huApoE4 TR mouse brain lysates at all 
three different points (12th, 32nd and 72nd week). My data is in line with most 
reports whereby significant loss of glucose activity were observed in clinical 
and mouse models suffering from neurological impairment (Gerozissis 2008; 
Liu, Liu et al. 2011). These observations led me to speculate that glucose was 
not effectively transported into cells. Further insulin assays showed no 
difference in the insulin level of both 12 and 32 week old huApoE TR mice. 
72 week old huApoE4 TR mice exhibited 25% higher brain insulin level. This 
might suggest that the brain has attempted to increase the amount of insulin in 
order to boost the glucose uptake in the cells. This is likely a feedback 
response due to prolong hypoglycaemic condition in the CNS. This is 
commonly observed in insulin resistant muscle cells whereby higher amount 
of insulin is required to allow the uptake of glucose into the cells. In summary, 
distinct glucose and insulin profiles were displayed in both animals and this 
may be due to huApoE isoform difference. This is also supported by reports of 
ApoE in associated with insulin in lipid metabolism studies (Descamps, 
Bilheimer et al. 1993; Ogbonna, Theriault et al. 1993). 
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In sharp contrast with the CNS, I did not pick up any difference in both the 
plasma glucose and insulin profiles of both huApoE TR mouse models. This 
indicates that plasma glucose and insulin may have little or no association with 
the CNS. It is likely that both the peripheral and CNS are mutually exclusive 
in huApoE TR mouse models. 
 
4.3.2 huApoE protein level in the CNS 
From the NPC studies, I learned that ApoE expression regulate the PI3K/AKT 
signalling pathway. Measurement of huApoE protein level was conducted via 
real time qPCR and Western blot analysis. The real time data showed 
consistent transcripts level in both huApoE TR mice across all three time 
points (12th, 32nd and 72nd week). Western blot densitometry analysis, 
surprisingly, showed up to 45% lower huApoE protein in huApoE4 (compared 
to huApoE3) TR mouse brain lysates. The protein disparity is not the result of 
varying expression in both animals but due to varying protein stability. Firstly, 
both huApoE isoforms are regulated by the same muApoE regulatory elements; 
secondly, there was no difference in the brain huApoE transcripts of both 
huApoE TR mouse models. Lastly, huApoE4 has been reported to be less 
stable and prone to degradation (Huang, Liu et al. 2001; Riddell, Zhou et al. 
2008) as compared to huApoE3. 
 
It is also interesting to note that lower glucose content was detected in the cells 
as early as the 12th week while the onset of huApoE degradation seem to be 
only visible at the 32nd week onwards . This indicates that, other than huApoE 
protein level, huApoE isoform may be responsible for lower glucose uptake in 
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the brain cells as early as the 12th week. The molecular mechanism linking 
huApoE isoforms and glucose metabolism in the CNS remain unsolved, 
however comparable observations have been reported (Drzezga, 
Riemenschneider et al. 2005; Reiman, Chen et al. 2005; Ercoli, Siddarth et al. 
2006; Rimajova, Lenzo et al. 2008; Langbaum, Chen et al. 2010; Reiman, 
Chen et al. 2010) 
 
4.3.3 Loss of IRS2 in the CNS of huApoE4 TR mouse model 
The cholesterol, glucose and insulin assays results prompted me to further 
investigate and identify possible molecular pathway/s which may lead to these 
observations. Parallel to my previous NPC studies, I decided to investigate the 
PI3K/AKT signalling pathway which plays a key role in glucose metabolism. 
IRS and IR-related proteins are involved in the upstream signalling of 
PI3K/AKT pathway. There was no change in the protein level of IRS1 despite 
huApoE isoform differences at all three different time points. However, I 
noticed significantly higher level of IRS2 in huApoE4 TR mice as early as the 
12th week. Interestingly, by 72nd  week, this trend reversed and it recorded up 
to 46% loss in IRS2 in huApoE4 TR TR mice.  
 
The IRS2 KO mouse model has been widely used as for diabetic and/or 
glucose metabolism studies. Dysregulation of IRS2 in different cell types have 
been shown to affect the regulation of glucose transport (Sadagurski, 
Weingarten et al. 2005). In the CNS, IRS2 has been suggested to be involved 
in brain growth, neuronal proliferation (Schubert, Brazil et al. 2003), synaptic 
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plasticity (Costello, Claret et al. 2012) and longevity (Taguchi, Wartschow et 
al. 2007).  
 
As discussed in the introduction, ApoE and ApoD are largely involved in the 
transportation of lipid in the CNS. Significant lower level of ApoE in the brain 
of huApoE4 TR mice may have affected the brain development at a young age. 
In order to compensate for this loss, up regulation of IGF1Rβ (to be discussed 
later) was observed. This in turn led to the notable increase in IRS2 as early as 
the 12th week. The significant loss of IRS2 in older mice (72 weeks old) was 
recorded. This coincides with clinical data whereby marked loss of IRS2 was 
also observed in elderly subjects with cognitive impairment. These changes 
also correlate with the severity of neurodegeneration (Freude, Schilbach et al. 
2009). 
 
4.3.4 PI3K/AKT signalling in the CNS of huApoE TR mouse models 
Protein analysis of IRβ showed little difference between both huApoE TR 
mouse models. However, I recorded up to 104% increment of IGF1Rβ in 12 
week old huApoE4 as compared to huApoE3 mouse. These data support 
earlier findings whereby IGF1Rβ may have resulted in notable higher IRS2 
protein in 12 week old huApoE TR mice. Further analysis of p-IRβ and p-
IGF1Rβ showed significant loss of these proteins in 32 and 72 week old 
female huApoE4 TR mice. The link between insulin receptor activity and 
IRS2 expression has been reported (White 2002; Brady 2004). Comparable 
observations were made in this study. 
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Tyrosine phosphorylation of IRS1 and IRS2 lead to the binding of SH2 
domains containing proteins such as the PI3K p85 subunit which in turn 
activates the PI3K p110 subunit (Farese, Sajan et al. 2005). This allows the 
conversion of PIP2 to PIP3 leading to downstream activation of AKT. My 
results showed loss of p-IRβ and IGF1Rβ proteins, followed by diminishing 
IRS2 and PI3K p85 proteins in huApoE4 TR female mice, in particular older 
mice (72 week old). PI3K is widely documented for its roles in periphery 
tissues such as liver, muscle and adipocytes, however there is also a growing 
interest on its functionality in the CNS. Local administration of PI3K inhibitor 
in the CNS has been shown to block insulin signalling pathway (Obici, Feng et 
al. 2002; Obici, Zhang et al. 2002). These further enforce the importance of 
PI3K and the loss of PI3K p85 may affect other downstream proteins of this 
signalling pathway. 
 
The loss of IRS2 was observed in 72 week old ApoE4 TR mice while loss of 
PI3K p85 subunit was observed in 32 and 72 week old ApoE4 TR mice. It is 
likely that other than IRS2, the expression of PI3K may be modulated by some 
other pathways. Existing data is unable to identify concrete evidence 
highlighting the effects of altered PI3K p85 subunit protein level to PI3K 
activity, and several reports shared similar challenge (Andreelli, Laville et al. 
1999; Rieusset, Chambrier et al. 2001; Rieusset, Roques et al. 2001; Barbour, 
Mizanoor Rahman et al. 2005). Regardless, PI3K is recognized as a key player 
in insulin signalling. The loss of PI3K p85 will lead to the suppression of AKT 
activity. This coincides with current observations; significant loss of p-AKT 
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Threonine 308 and Serine 473 in older huApoE4 as compared to huApoE3 TR 
mice.  
 
Lower PI3K/AKT signalling has been shown to impair neuroprotection 
(Dudek, Datta et al. 1997; Hong, Kwon et al. 2001; Hirai, Hayashi et al. 2004; 
Manning and Cantley 2007). The genetic effects of huApoE4 in the CNS of 
mice only surfaced at later time point. This indicates that the overall 
attenuated activity of PI3K/AKT signalling observed in huApoE4 animals is 
associated with the effects of ageing. 
 
4.3.5 Lower GluT4 expression complements the observations in 
PI3K/AKT signalling pathway 
The expression of GluT4 is significantly lower in the CNS of huApoE4 TR 
mouse at older time point (72 week old). This is likely attributed by the lower 
PI3K/AKT signalling. Previous animal and cell culture studies have also 
showed that PI3K/AKT signalling pathway regulates GluT4 activity (Cong, 
Chen et al. 1997; Hernandez, Teruel et al. 2001; Huang, Huang et al. 2009). 
Comparable observations were made in T2DM patients whereby the 
transcripts for PI3K are much lower in the skeletal muscle and adipose tissues 
(Ducluzeau, Perretti et al. 2001). 
 
In summary, the CNS of huApoE3 and huApoE4 TR mouse models exhibit 
different PI3K/AKT signalling profiles with increasing age. This is coupled 
with significant loss of GluT4 protein expression and abnormally higher 
insulin in older huApoE4 TR mice. It is possible that the attenuated 
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PI3K/AKT signalling led to the loss of GluT4 protein expression. As part of 
the body’s effort to compensate for the loss of GluT4 and together with falling 
glucose concentration in the CNS, it drove the insulin level higher. 
  







Distinct glucose and insulin profiles were observed in the CNS of both 
huApoE targeted replacement mouse models. In fact, most of these differences 
were prominent in older mice. Physiological impact of ageing, huApoE 
genotype and protein level were three of the key areas I have addressed in this 
study. 
  
Figure 21 Overall representation of my findings addressing the effects of
huApoE isoform and ageing on PI3K/AKT signalling in the CNS 
Varying glucose and insulin profiles were observed in the CNS. Further
analysis showed attenuated PI3K/AKT signalling in the CNS. The two major
variables in this study are huApoE isoform and ageing.  
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The huApoE3 and E4 TR mouse models are excellent tool for us to study the 
effect of huApoE genotype on the physiology of the animal. ApoE isoform has 
been reported to be associated with hypometabolism, particularly in the CNS 
and the effects were evident in elderly population (Langbaum, Chen et al. 
2010; Tao, Liu et al. 2011; Chen, Ayutyanont et al. 2012). Limited 
information is available addressing the link between huApoE and PI3K/AKT 
signalling except for a recent microarray study (Simpson, Ince et al. 2011). 
These results together with existing literature provide considerable amount of 
information linking these three factors.  
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CHAPTER 5 
HUMAN APOLIPOPROTEIN E 
POLYMORPHISM AFFECTS INSULIN 
SIGNALLING IN THE LIVER OF HUAPOE TR 
MOUSE MODELS 
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5 Human apolipoprotein E polymorphism affects insulin signalling in the 
liver of huApoE TR mouse models 
5.1 Introduction 
5.1.1 Apolipoprotein E isoforms affects plasma cholesterol 
ApoE plays a central role in the regulation of periphery lipoproteins. It 
functions as a ligand for LDL-, VLDL- and remnant receptors. It is largely 
synthesized by hepatocytes and macrophages in the peripheral system. More 
importantly, ApoE is responsible for the clearance of lipoproteins through the 
reverse cholesterol transport system by the liver. This process reduces plasma 
cholesterol associated with atherosclerosis susceptibility (Mahley 1988; 
Mahley and Rall 2000). HuApoE3 and E4 bind to LDLR with different 
affinity. This gives rise to varying efficiency in the clearance of plasma 
cholesterol. Other than cholesterol, clinical study has also showed 
significantly lower plasma ApoE in huApoE4 carrier (Larson, Ordovas et al. 
2000). 
 
HuApoE4 carriers are associated with increase plasma cholesterol 
concentration and a higher risk of atherosclerosis. In particular, huApoE4 
carriers have exceptionally high LDL-cholesterol level (Gylling, Kontula et al. 
1995; Mahley and Rall 2000; Han, Heath et al. 2002; Tascilar, Dursun et al. 
2009). 
 
ApoE-deficient mice have been reported to develop severe dyslipidemia and 
atherosclerotic lesions (Nakashima, Plump et al. 1994). Mouse models 
expressing huApoE3 and E4 have normal cholesterol profiles and do not 
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develop atherosclerosis (Sullivan, Mezdour et al. 1997; Knouff, Hinsdale et al. 
1999). Under western high-fat diet, both mouse models suffer from 
hypercholesterolemia and huApoE4 TR mouse model displays more severe 
symptoms. In line with this observation, a report has also shown that ApoE4 
carriers are more sensitive to diet and exhibit wider variation in cholesterol 
level (Kallio, Salmenpera et al. 1998). 
 
5.1.2 Apolipoprotein E and glucose metabolism 
ApoE polymorphism has been suggested to modify the effect of insulin on 
coronary artery disease, body mass, TG, total and LDL cholesterol levels 
(Laakso, Kesaniemi et al. 1991; Despres, Verdon et al. 1993; Orchard, Eichner 
et al. 1994; Valdez, Howard et al. 1995). Diabetes has also been reported to be 
associated with 2-4 fold higher risk of coronary artery disease (Soedamah-
Muthu, Chaturvedi et al. 2004). It is speculated that glucose dysfunction may 
be linked to ApoE and/or cholesterol metabolism in the peripheral system. A 
recent study on HuApoE TR mouse models drew similar conclusion. 
HuApoE4 TR mice gained less weight but showed signs of impaired glucose 
tolerance as compared to huApoE3 TR mice (Arbones-Mainar, Johnson et al. 
2010). 
 
On the other hand, some literature indicates no correlation between ApoE 
polymorphism and insulin resistance. However, the author did highlight that 
there are some limitations to his study (Meigs, Ordovas et al. 2000). In 
summary, the molecular mechanisms associating insulin levels or insulin 
90 | P a g e  
 
resistance and ApoE isoform remains elusive (Shriver, Boerwinkle et al. 1991; 
Meigs, Ordovas et al. 2000). 
 
5.1.3 Knowledge from previous studies 
In the last two chapters, I learned that differential ApoE expression and 
isoform have an impact on the CNS. Specifically, my observations showed 
distinct changes in the PI3K/AKT signalling pathway in the brain. These 
effects appear to be limited to the CNS as the cholesterol, insulin and glucose 
results between the plasma and the CNS exhibited different profiles. However, 
insulin dosage to the peripheral system of human subjects with different 
huApoE genotype has been shown to have differential cognitive effect (Craft, 
Asthana et al. 1999; Craft, Asthana et al. 2003). It is suggested that huApoE 
genotype may influence the patients’ sensitivity to insulin. Other than isoform 
differences, I found significantly lower huApoE4 as compared to huApoE3 in 
the CNS of these mouse models. Similar trend has been reported in human 
plasma ApoE concentration (Larson, Ordovas et al. 2000). The expression 
level of ApoE in the liver of these huApoE TR mouse models has not been 
investigated. 
 
5.1.4 Experimental considerations 
Other than huApoE genotype variation, this study will study the expression 
level of huApoE in the liver since it is the major organ synthesizing huApoE. I 
have also incorporated ageing as a variable for this study. These animals were 
kept up to 72 weeks to investigate the effect of ageing. Only female animals 
were used for this study. Cholesterol, glucose and insulin assays were 
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conducted in huApoE TR mouse liver lysates to determine potential 
physiological differences. Earlier data showed distinct assay profiles in both 




Published data suggest that differential huApoE protein levels and/or huApoE 
genotype is/are associated cholesterol and possibly glucose metabolism. I am 
interested to find out if PI3K/AKT signalling in the peripheral system which 
plays a key role in the regulation of glucose and insulin exhibits different 
profiles as observed in the CNS of huApoE TR mouse models. 
 
It hypothesized that huApoE isoform differences together with ageing may 
affect glucose metabolism in the liver. In line with my earlier CNS data, it is 
speculated the PI3K/AKT signalling pathway may be affected. No publication 
has addressed glucose metabolism and/or PI3K/AKT signalling in these 
mouse models over a time course. The academic impact of deciphering this 
molecular mechanism may be useful and complementary to earlier CNS data.  
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5.2 Results 
5.2.1 Total cholesterol in the liver of female huApoE3 and huApoE4 TR 
mouse models 
 
Figure 22 Total amount of cholesterol of liver lysates in female huApoE3 
and huApoE4 TR mice 
Amplex red cholesterol assays of samples from liver lysate across all three 
time points (12th, 32nd and 72nd week) of female huApoE3 (white bar) and 
female huApoE4 (grey bar) TR mice. The liver lysate was normalized to its 
total protein measured via BCA method. Each value represents the mean ± SD 
for individual mouse liver samples (n = 5 at each time point for each mouse 
line). Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p value ≤ 0.001 
using Student’s t-test. 
 
No significant change was observed in the cholesterol content of the liver 
tissue lysates (Figure 22) of huApoE3 and huApoE4 TR mice at 12th, 32nd and 
72nd week time points 
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Protein analysis via Western blot on liver samples of these two mouse models 
indicate significantly lower huApoE protein expression in huApoE4 TR at 12 
week old (-24%), 32 week old (-42%) and 72 week old (-84%) female mice 
(Figure 23). These results suggest lower amount of huApoE in huApoE4 TR 
as compared to huApoE3 TR mice. This phenomenon was observed in liver 
samples as early as the 12th week. 
Figure 23 Liver huApoE protein expression level in huApoE3 and 
huApoE4 TR female mice 
Western blot analysis of human Apolipoprotein E (huApoE) and β-actin 
was immnunoblotted to ensure similar gel loading of the starting material
in each sample. Densitometry analysis of huApoE relative to β-actin level 
in female huApoE3 (white bar) and female huApoE4 (grey bar) TR mice 
were performed using the NIH ImageJ software. Each value represents the
mean ± SEM for individual mouse liver sample (n = 3 at each time point 
for each mouse line). Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p 
value ≤ 0.001 using Student’s t-test.  
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5.2.3 Glucose and insulin level in the liver of female huApoE3 and 









Relative similar total glucose was detected in the 12 and 32 week old liver 
lysates. However notable increase in total glucose (+37%) of huApoE4 liver 
lysate was observed in the 72nd week time point (Figure 24). Insulin assays 
showed little change at the 12th week time point. Insulin was significantly 
lower in huApoE4 liver lysate as compared to huApoE3 at both 32nd (-42%) 
and 72nd (-38%) week time points (Figure 24).  
Figure 24 Total glucose and insulin in liver lysates of female huApoE3 and
huApoE4 TR mice 
Glucose assays of samples from liver lysates across all three time points (12th,
32nd and 72nd week) of female huApoE3 (white bar) and female huApoE4 (grey
bar) TR mice. Insulin assays of samples from liver lysates across all three time
points (12th, 32nd and 72nd week) of female huApoE3 (solid line) and female 
huApoE4 (dotted line) TR mice. Glucose and insulin readings were normalized 
to its total protein measured via BCA method. Each value represents the mean ±
SD for individual mouse liver sample (n ≤ 3 at each time point for each mouse
line). Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p value ≤ 0.001 using
Student’s t-test. 
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5.2.4 PI3K-AKT protein profile in the liver of huApoE3 and huApoE4 TR 
mice 
 
Western blot densitometry studies were conducted in liver tissue lysates. 
There was little difference in the expression of IRS1 at earlier time points, 12th 
and 32nd week. At 72nd week, significant loss of IRS1 expression (-95%) 
(Figure 25A and 25C) was observed in huApoE4 as compared to huApoE3 TR 
mice. For IRS2, I observed relatively uniform expression in 12 – 72 week old 
liver lysates of both mouse models (Figure 25A and 25B).  
 
IGF1Rβ was evenly expressed in huApoE3 and huApoE4 TR female mouse 
liver lysates at all three time points (Figure 26A and 26B). At the 12th and 32nd 
week, there was no change in the expression of IRβ in both mouse models but 
at the 72nd week, I found significant increase in the expression of IRβ (+48%) 
in huApoE4 TR mice (Figure 26A and 26C). p-IRβ and p-IGF1Rβ showed no 
expressional difference in 12 and 32 week old animals. Significant drop in p-
IRβ and p-IGF1Rβ (-93%) expression was observed in 72 week old huApoE4 
TR mice as compared to huApoE3 TR mice (Figure 26A and 26D). 
 
The liver lysates analysis of PI3K p85 and p110 showed little or no change in 
the expression of these proteins in 12 and 32 week old huApoE TR female 
mice. Notable loss of both PI3K p85 (-42%) and p110 (-71%) proteins were 
observed in older female huApoE TR mice (72 week old) (Figure 27). 
Subsequently, I had also studied the expression of AKT proteins in female 
huApoE TR mouse liver samples. Comparable expression of AKT was 
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observed in both huApoE3 and huApoE4 TR female mice at all three time 
points (Figure 28A and 28C). There was no change in p-AKT S473 in 12 
week old mice while significant loss of p-AKT S473 was observed at 32 (-
58%) and 72 (-44%) week old huApoE4 as compared to huApoE3 female 
mice (Figure 28A and 28B). Similar trend was observed for p-AKT T308 but 
the onset of this loss was only observed at 72 week old huApoE4 (-54%) mice. 
12 and 32 week old mice have relatively similar expression of p-AKT T308 
(Figure 28A and 28D). Lastly, there was little or no change in GluT4 at 12 and 
32 week old huApoE TR mice. However at the 72nd week time point, there is 
39% loss of GluT4 in huApoE4 as compared to huApoE3 TR female mouse 
liver lysates (Figure 29). 
  










Figure 25 Liver insulin receptor substrate (IRS) proteins expression level
of huApoE3 & E4 TR mice  
(A) Western blot analysis of insulin receptor substrate 1 (IRS1) and insulin
receptor substrate 2 (IRS2). β-actin was immnunoblotted  to ensure similar gel
loading of the starting material in each sample. Densitometry analysis of (B)
IRS1 and (C) IRS2 in female huApoE3 (white bar) and female huApoE4 (grey
bar) TR mice were performed using the NIH ImageJ software. Each value
represents the mean ± SEM for individual mouse liver samples (n = 3 at each
time point for each mouse line). Whereby, * p value ≤ 0.05, ** p value ≤ 0.01,
*** p value ≤ 0.001 using Student’s t-test. 
 








Figure 26 Liver insulin receptor (IR) proteins expression level of huApoE3
& E4 TR mice  
(A) Western blot analysis of phosphorylated insulin receptor β (p-IRβ),
phosphorylated insulin growth factor receptor β (p-IGFRβ), insulin receptor β 
(IRβ) and insulin growth factor receptor β (IGF1Rβ). β-actin was
immnunoblotted  to ensure similar gel loading of the starting material in each
sample. Densitometry analysis of (B) p-IRβ + p-IGFRβ , (C) IRβ and (D)
IGF1Rβ relative to β-actin level in female huApoE3 (white bar) and female
huApoE4 (grey bar) TR mice were performed using the NIH ImageJ software.
Each value represents the mean ± SEM for individual mouse liver sample (n =
3 at each time point for each mouse line). Whereby, * p value ≤ 0.05, ** p
value ≤ 0.01, *** p value ≤ 0.001 using Student’s t-test. 









Figure 27 Liver phosphatidylinositol 3-kinases (PI3K) proteins expression
level of huApoE3 & E4 TR mice 
(A) Western blot analysis of phosphatidylinositol 3-kinases p110 (PI3K p110)
and phosphatidylinositol 3-kinases p85 (PI3K p85). β-actin was
immnunoblotted  to ensure similar gel loading of the starting material in each
sample. Densitometry analysis of (B) PI3K p110, (C) PI3K p85 relative to β-
actin level in female huApoE3 (white bar) and female huApoE4 (grey bar) TR
mice were performed using the NIH ImageJ software. Each value represents the
mean ± SEM for individual mouse liver samples (n = 3 at each time point for
each mouse line). Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p value ≤
0.001 using Student’s t-test. 







Figure 28 Liver AKT proteins expression level of huApoE3 & E4 TR mice  
(A) Western blot analysis of phosphorylated AKT Serine 473 (p-AKT S473),
phosphorylated AKT Threonine 308 (p-AKT T308) and AKT. β-actin was
immnunoblotted  to ensure similar gel loading of the starting material in each
sample. Densitometry analysis of (B) p-AKT S473, (C) AKT and (D) p-AKT
T308 relative to β-actin level in female huApoE3 (white bar) and female
huApoE4 (grey bar) TR mice were performed using the NIH ImageJ software.
Each value represents the mean ± SEM for individual mouse liver samples (n =
3 at each time point for each mouse line). Whereby, * p value ≤ 0.05, ** p
value ≤ 0.01, *** p value ≤ 0.001 using Student’s t-test. 









Figure 29 Liver glucose transporter 4 protein expression level of huApoE3
& E4 TR mice  
Western blot analysis of glucose transporter 4 (GluT4). β-actin was
immnunoblotted  to ensure similar gel loading of the starting material in each
sample. Densitometry analysis of GluT4 relative to β-actin level in female
huApoE3 (white bar) and female huApoE4 (grey bar) TR mice were performed
using the NIH ImageJ software. Each value represents the mean ± SEM for
individual mouse liver sample (n = 3 at each time point for each mouse line).
Whereby, * p value ≤ 0.05, ** p value ≤ 0.01, *** p value ≤ 0.001 using
Student’s t-test. 
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5.3 Discussion 
5.3.1 Cholesterol and glucose metabolism in the liver 
My data showed that the regulation of cholesterol across the blood plasma, 
liver and brain lysates is not affected by the genotype and age differences. 
Mouse models expressing huApoE3 and E4 have been shown to have similar 
cholesterol profiles and do not develop atherosclerosis (Sullivan, Mezdour et 
al. 1997; Knouff, Hinsdale et al. 1999). My results showed similar 
observations and ageing did not affect the cholesterol level. However, under 
western high-fat diet, both mouse models suffer from hypercholesterolemia. 
The same study also showed that ApoE4 TR animals are more sensitive to diet 
and exhibit wider variation in cholesterol level (Kallio, Salmenpera et al. 
1998). This is in line with clinical data whereby HuApoE4 carriers are 
associated with increase plasma cholesterol concentration and a higher risk of 
atherosclerosis (Gylling, Kontula et al. 1995; Mahley and Rall 2000; Han, 
Heath et al. 2002; Tascilar, Dursun et al. 2009).  
 
Earlier assay studies of glucose and insulin on brain lysates and blood plasma 
showed distinct profiles in both the peripheral and CNS. In this study, notable 
glucose and insulin changes were also observed in the liver of 72 week old 
huApoE TR mice. Although the circulating blood system was not affected, the 
regulation of glucose and insulin in the liver exhibited changes associated with 
ApoE genetic variation, particularly in older animals.  
 
ApoE polymorphism has been reported to affect the effects of insulin on 
coronary artery disease, body mass, TG, total and LDL cholesterol levels 
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(Laakso, Kesaniemi et al. 1991; Despres, Verdon et al. 1993; Orchard, Eichner 
et al. 1994; Valdez, Howard et al. 1995). A recent study on huApoE TR mouse 
models drew similar conclusion. It was found that huApoE4 TR mice gained 
less weight but showed signs of impaired glucose tolerance as compared to 
huApoE3 mice (Arbones-Mainar, Johnson et al. 2010).  
 
Data from this study showed higher level of glucose and lower amount of 
insulin in the liver of huApoE4 TR mice as compared to huApoE3. These 
results suggested that huApoE genotype and/or protein level may influence the 
regulation of glucose and insulin in the peripheral system of older animals, 
regardless of cholesterol level. In order to verify this statement, I have 
explored key the PI3K/AKT signalling pathway which may contribute to this 
phenomenon.  
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5.3.2 HuApoE isoforms and PI3K-AKT signalling pathway 
Other than cholesterol and glucose assays, clinical studies also showed 
significantly lower plasma ApoE in huApoE4 carrier (Larson, Ordovas et al. 
2000). This is particularly interestingly as both the liver and brain tissues in 
huApoE TR mice displayed lower huApoE protein level too. Glucose and 
insulin concentration have been associated with varying huApoE level (Dashti, 
Williams et al. 1989; Kawashima, Chen et al. 2009; Arbones-Mainar, Johnson 
et al. 2010). 
 
Likewise to the CNS, significantly lower liver huApoE expression was 
observed in huApoE4 TR mouse models across all time points. This supported 
my earlier conclusion and existing reports (Huang, Liu et al. 2001; Riddell, 
Zhou et al. 2008)  that huApoE4 may be more prone to degradation than 
huApoE3 thus leading to the differences. 
 
Preliminary Western blot analysis showed severe loss of IRS1 in huApoE4 TR 
liver lysates as compared to huApoE3 at the 72nd week time point while IRS2 
showed little change across all time points. Serine/ Threonine phosphorylation 
of IRS1 has been reported to trigger IRS1 degradation (Pederson, Kramer et al. 
2001). Up to 93% loss of p-IRβ and p-IGF1Rβ were also observed in the liver 
of 72 week old huApoE4 TR mice. The above two findings demonstrated that 
huApoE isoforms may regulate IRS proteins activation and possibly 
associated with ageing.  
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Decreased insulin binding followed by reduced receptor tyrosine kinase 
activity and increased IRS1 protein degradation have been showed in liver, 
muscle and adipocytes of TD2M mouse models (Kerouz, Horsch et al. 1997; 
Paz, Hemi et al. 1997; Li, DeFea et al. 1999; Pederson, Kramer et al. 2001). 
IRS1 is the main docking protein for downstream signalling to PI3K/AKT 
signalling pathway. 
 
Western blot results showed that lower PI3K p85 and p100 proteins which are 
likely due to reduced tyrosine activated IRS1 in 72 week old huApoE4 as 
compared to huApoE3 TR mice. The importance of PI3K and its role in the 
peripheral system such as the liver (Farese, Sajan et al. 2005) has been 
highlighted in the previous discussion. These findings also showed 
significantly lower AKT Serine 473 and Threonine 308 phosphorylation in 
older mice. The entire series of data demonstrated strong correlation between 
PI3K/AKT signalling pathway and the effects of huApoE isoforms with 
ageing. An attenuated PI3K/AKT signalling due to reduced IRβ activity and 
IRS1 degradation are consistently recorded at later time point (72nd week). 
Western blot mapping PI3K/AKT signalling pathway is possibly associated 
with the preliminary glucose and insulin assays. In addition, ApoE has been 
reported to be involved in insulin and glucose metabolism (Dashti, Williams et 
al. 1989; Kawashima, Chen et al. 2009; Arbones-Mainar, Johnson et al. 2010). 
 
Western blot analysis also exhibited loss of GluT4 across all time points in 
huApoE4 as compared to huApoE3 TR liver lysates. The down regulation of 
the PI3K/AKT signalling pathway was only prominent in older huApoE4 TR 
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mice. In contrast, the onset for the loss of GluT4 was consistently found across 
all time points. It is possible that loss of GluT4 may be due to several factors 
other than PI3K/AKT signalling pathway (Dohm, Elton et al. 1991; Ducluzeau, 
Perretti et al. 2001; Kampmann, Christensen et al. 2011). One of these 
pathways includes the AMPK signalling pathway which regulates glucose 
utilization via the expression and translocation of GluT4 to the plasma 
membrane. This process is independent of insulin (Hayashi, Hirshman et al. 
1998; Russell, Bergeron et al. 1999; Witczak, Sharoff et al. 2008). 
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5.4 Summary 
In summary, the hepatic system of huApoE3 and huApoE4 TR mouse models 
exhibit distinctive glucose, insulin and PI3K/AKT signalling profiles, 
particularly in older mice. In addition, significantly attenuated PI3K/AKT 
signalling pathway was mapped out in the huApoE4 TR mouse hepatic system. 
Unfortunately, it remains a challenge to differentiate if these results were 
associated with varying huApoE isoform or protein level. Notable loss of 
GluT4 protein expression in huApoE4 TR mice was also observed. It is 
possible that PI3K/AKT signalling pathway is involved in the regulation of 
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CHAPTER 6 
 CONCLUDING REMARKS 
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6 Concluding remarks 
The biology I have focused on revolves around ApoE and its impact on the 
regulation of lipid and glucose, especially in the CNS. Dysregulation of lipid 
and glucose have been associated with neurological, hypercholesterolemia and 
other metabolic disease such as T2DM. Longitudinal studies on NPC and 
huApoE mouse models had also allowed me to address the importance of 
ageing. This is especially in huApoE TR mouse model whereby dysregulation 
of glucose metabolism is largely prevalent especially in older mice. 
 
The initial NPC mouse model study concluded that varying muApoE 
expression level and lipid metabolism may have disrupted the PI3K/AKT 
signalling pathway. I was also able to identify a possible role for Aebp1 in the 
CNS via PI3K/AKT signalling pathway. In addition to these results support 
the trio relationship across PI3K/AKT, glucose (insulin) and lipid (ApoE) 
metabolism in the CNS. 
 
I have extended my study of ApoE and lipid metabolism into huApoE TR 
mouse models. Preliminary results produce virtually no change in the 
cholesterol profiles between both isoforms across all time points. It was 
surprising that ageing did not affect the cholesterol profiles. Conversely, I did 
noticed varying glucose and insulin profiles between the two huApoE TR 
mouse models in both the peripheral and CNS. Comparable to the NPC study, 
severely attenuated PI3K/AKT signalling pathway was recorded in both the 
peripheral and CNS of huApoE TR mice.  
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One of the major limitations of huApoE TR animal studies is differentiating if 
these observations are consequences of varying huApoE isoforms or protein 
levels. The data from NPC mouse model leans towards the hypthesis that 
varying ApoE level may be the causative factor. Regardless, these data 
support the underlying hypothesis that PI3K/AKT signalling pathway and the 
regulation of glucose might be linked to huApoE and ageing.  
 
Conclusively, this thesis addressed the importance of ApoE genotype and its 
association with potential glucose metabolic pathways, possibly neurological 
and metabolic diseases. The effects of isoform differences become more 
evident with the effects of ageing. 
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